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1/3 Zn(II) (!), and TRIL9CL23H + 1/3 Hg(II) + 5/3 Zn(II) (▲). There is no shift in 
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Figure 2-9. Ribbon diagrams of the [Hg(II)]S[Zn(II)(OH2/OH-)]N(CSL9PenL23H)3n+ 
parallel 3SCC (one of two different three-helix bundles present in the ASU) at pH 
8.5. Shown are the main chain atoms represented as helical ribbons (cyan) and the 
Pen and His side chains in stick form (sulfur = yellow, nitrogen = blue, oxygen = 
red). a) One of two trimers found in the ASU of the crystal structure. b) A top-down 
view of the structural T-shaped thiolate site, Hg(II)S3, confirming one of the 
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of increasing [pep3] for the reverse titration. ............................................................. 92 
Figure 2-13. Competitive Zn(II)-binding titrations against Zincon at pH 9.0 for 
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(5 µM Zn(II)Zi + pep3) direction. a) Representative UV-Vis spectra for the titration 
in the forward direction and b) in the reverse direction. c) Plot of absorbance at 620 
nm as a function of increasing [Zincon] for the forward titration and d) as a function 
of increasing [pep3] for the reverse titration. ............................................................. 93 
Figure 2-14. Competitive Zn(II)-binding titrations against Zincon for (TRIL2WL23H)3 
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concentration of substrate, without averaging) to the Michaelis-Menten equation in 
Prism 5 (GraphPad Software).35 The fitting equation used for the pH-dependence (eq 
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(TRIL9CL23H)3n+ in 50 mM HEPES (pH 7.5-8.0) or CHES (pH 8.5-9.5), both 0.1 
M Na2SO4. Error bars result from fitting all individual initial rates measured (three 
per concentration of substrate, without averaging) to the Michaelis-Menten equation 
in Prism 5 (GraphPad Software).35 The fitting equation used for the pH-dependence 
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inhibition model in Prism 5 (GraphPad Software).35 The global data yields the 
reported KI and corresponding error. Data shown consists of each individual 
measured initial rate and does not represent averages. Fitting the same data to a 
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competitive inhibition model.37 b) Lineweaver-Burke (double-reciprocal) plots 
corresponding to the data in a). Visual inspection of the intersection of linear fits to 
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[Hg(II)]S[Zn(II)(OH2/OH-)]N(CSL9PenL23H)3n+ (pdb 3PBJ) 12. (c) Overlay of the 
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in tan (pdb 2CBA), and adamalysin II in grey (pdb code 1IAG). a) Top-down view 
of the overlay with CAII. The solvent molecule associated with 
[Hg(II)]S[Zn(II)(OH2/OH-)]N(CSL9PenL23H)3n+ is shown in red and that associated 
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spectra vs wavelength. b) A plot of the absorbance at 247 nm (characteristic of 
HgS3) as a function of equivalents of HgCl2 per trimer to show that maximal 
absorbance occurs at one equivalent of Hg(II) per trimer. ...................................... 126 
Figure 3-2. UV-Vis titration of HgCl2 to a solution containing 30 µM TRIL9CL19H in 
50 mM CHES buffer (0.1 M Na2SO4) at pH 8.5. a) A plot of absorbance difference 
spectra vs wavelength. b) A plot of the absorbance at 247 nm (characteristic of 
HgS3) as a function of equivalents of HgCl2 per trimer to show that maximal 
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Figure 3-3. Folding of TRIL9HL23C (apo and + 1/3 Hg(II)) and TRIL9CL19H (apo and 
+ 1/3 Hg(II)) as monitored by CD. a) CD spectra of TRIL9HL23C and 
TRIL9HL23C + 1/3 Hg(II) at pH 8.5 and 25 °C. The molar ellipticities [Θ] at 222 
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titrations represented by [Θ] at 222 nm vs denaturant concentration for 
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TRIL9CL19H + 1/3 Hg(II) at pH 8.5 and 25 °C. The [Θ] values at 222 nm are ~ -
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Figure 3-4. Comparison of the unfolding of TRIL9HL23C (apo and + 1/3 Hg(II)) and 
TRIL9CL19H (apo and + 1/3 Hg(II)) to TRIL23H and TRIL9CL23H (apo and + 
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vs denaturant concentration for TRIL23H, TRIL9CL23H, TRIL9HL23C, and 
TRIL9CL19H. For each of the Cys-containing peptides, when comparing the apo 
versions and the Hg(II)-bound peptides, the midpoint is shifted to a higher 
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represented by [Θ] at 222 nm vs denaturant concentration for GRL2WL16CL30H 
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Figure 3-7. Competitive Zn(II)-binding titrations against Zincon at pH 7.5 for 
[Hg(II)]S(TRIL9HL23C)3-, [Hg(II)]S(TRIL9CL19H)3-, and 
[Hg(II)]S(GRL2WL16CL30H)3-. Plots of absorbance at 620 nm vs [Zincon] for the 
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10 µM [Hg(II)]S[Zn(II)(OH2/OH-)]N(TRIL9CL19H)3n+, and c) 10 µM 
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[Hg(II)]S(TRIL9HL23C)3-, [Hg(II)]S(TRIL9CL19H)3-, and 
[Hg(II)]S(GRL2WL16CL30H)3-. Plots of absorbance at 620 nm vs [Zincon] for the 
forward titrations of a) 10 µM [Zn(II)(OH2/OH-)]N[Hg(II)]S(TRIL9HL23C)3n+, b) 
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Figure 3-9. pH-dependency of the catalytic efficiency for pNPA hydrolysis by Zn(II)-
bound TRI peptides: [Hg(II)]S[Zn(II)(OH2/OH-)]N(TRIL9CL23H)3n+ (●), 
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(TRIL9HL23C)3n+ (▲), [Hg(II)]S[Zn(II)(OH2/OH-)]N(TRIL9CL19H)3n+ (▼). Error 
bars result from fitting all individual initial rates measured (three per concentration 
of substrate, without averaging) to the Michaelis-Menten equation in Prism 5 
(GraphPad Software).34 The fitting equation used for the pH dependence (eq 1) is 
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substrate concentration in the presence of 0, 0.1, 0.25, and 0.5 M KOAc fitted to a 
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yields the reported KI and corresponding error. Data shown consists of each 
measured individual initial rate and does not represent averages. Fitting the same 
data to a mixed inhibition model yielded α ≈ 3 x 1013, supporting the assignment of a 
competitive inhibition model.54 b) Lineweaver-Burke (double-reciprocal) plots 
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Figure 3-13. pH-dependency of kcat/KM for pNPA hydrolysis by 
[Hg(II)]S[Zn(II)(OH2/OH-)]N(GRL2WL16CL30H)3n+. Error bars result from fitting 
all individual initial rates measured (three per concentration of substrate, without 
averaging) to the Michaelis-Menten equation in Prism 5 (GraphPad Software).34 The 
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Figure 4-1. Folding of TRIL9CL19TL23H (apo and + 1/3 Hg(II)) as monitored by CD. 
a) CD spectra of TRIL9CL19TL23H and TRIL9CL19TL23H + 1/3 Hg(II) at pH 
8.5 and 25 °C. The molar ellipticities [Θ] at 222 nm are ~ -7700 and ~ -21300 deg 
dmol-1 cm2, respectively.  b) GuHCl denaturation titrations represented by the [Θ] at 
222 nm vs denaturant concentration for TRIL9CL19TL23H and 
TRIL9CL19TL23H + 1/3 Hg(II). ........................................................................... 159 
Figure 4-2. Folding of GRL16CL26TL30H (apo and + 1/3 Hg(II)) and 
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respectively.  d) GuHCl denaturation titrations represented by [Θ] at 222 nm vs 
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Figure 4-3. Comparison of the unfolding of TRIL9CL23H (apo and + 1/3 Hg(II)) to 
GRL16CL26TL30H (apo and + 1/3 Hg(II)) and GRL16CL26DL30H (apo and + 1/3 
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GRL16CL26TL30H, and GRL16CL26DL30H. For each of the Cys-containing 
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Figure 4-4. C Competitive Zn(II)-binding titrations against Zincon at pH 7.5 for 
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Figure 4-5. Competitive Zn(II)-binding titrations against Zincon at pH 9.0 for 
[Hg(II)]S(GRL16CL26TL30H)3n- and [Hg(II)]S(GRL16CL26DL30H)3n-. Plots of 
absorbance at 620 nm vs [Zincon] for the forward titrations of a) 2 µM 
[Zn(II)(OH2/OH-)]N[Hg(II)]S(GRL16CL26TL30H)3n+, b) 2 µM 
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Figure 4-6. 113Cd NMR spectra of a solution of 10 mM (TRIL23H)3 and 0.9 equiv. 
113Cd(NO3)2 at different pH values from 5.6 to 9.8. The titration was initiated at low 
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Figure 4-8. UV-Vis titration of CoSO4 into a solution of 0.44 mM (TRIL2WL23H)3 at 
pH 7.6 in 50 mM HEPES buffer, 0.1 M Na2SO4. The data are plotted as molar 
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absorbance at 517 nm (λmax) vs [CoSO4]. The black circles represent the raw 
absorbance data and the magenta triangles represent the absorbance corrected for 
non-specific binding, as described in the Results section. The concentration of 
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Fundamental studies on structural stabilization and hydrolytic catalysis in a family 
of de novo designed α-helical three-stranded coiled coils are presented. Basic principles 
are used to discriminate structural and catalytic sites (Hg(II)Cys3 and Zn(II)His3). 
Spectroscopy, X-ray crystallography, and kinetic studies are exploited to characterize 
these sites. 
 X-ray crystal structures of these metallopeptides ([Hg(II)]S(Zn(II)(OH2/OH-
)]N(CSL9PenL23H)3n+) are determined to 2.2 Å resolution (pH 7.5 and 8.5). Both 
structures contain a tetrahedral ZnN3X site, like the active site of carbonic anhydrase 
(CA). At low pH a mixture of HgS2 and HgS3 centers is observed, while the high pH 
form exclusively shows HgS3. Denaturation studies verify the HgS3 site provides 
structural stability, while kinetic analysis of [Hg(II)]S[Zn(II)(OH2/OH-)]N 
(TRIL9CL23H)3n+ towards non-physiological substrate, p-nitrophenyl acetate (pNPA), 
confirms the ZnN3O site is hydrolytically active with a maximal efficiency (31 M-1 s-1) 
only ~100-fold less than the fastest CA and pKa ~2 units higher (9.0 vs 6.8). More 
significantly, analysis towards physiological substrate (CO2) confirms the design of a 
minimal Zn(II)-binding site with a catalytic efficiency (~2.6 x 105 M-1 s-1) within ~400-
fold of a highly evolved enzyme. This minimal active site structure becomes even more 
competitive with CAII mutants that exclude important secondary hydrogen-bonding 
interactions. 
Variation of the position of the ZnN3O site along the sequence of the peptides 
(TRIL9HL23C, TRIL9CL19H) and insertion into a longer, more stable sequence 
(GrandL2WL16CL30H) demonstrates that while location can be used to control binding 
affinity, solvent, substrate, and inhibitor access, Zn(II)-OH2 pKa, and catalytic rate, the 
maximal catalytic efficiency remains significantly high. Kinetic analysis in the absence of 
the structural site ([Zn(II)(OH2/OH-)]N(TRIL2WL23H)3n+) yields similar parameters 
demonstrating that this extra stability is not detrimental to the function of the second site. 
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 Polar residues (Thr, Asp) are incorporated into Grand (GrandL16CL26TL30H, 
GrandL16CL26DL30H) for implementing secondary interactions involving hydrogen 
bonding in order to fine-tune the designed hydrolytic site. These substitutions do not 
result in large changes to the catalytic efficiency; however, Zn(II)-binding affinities 
increase ~70-fold. Co(II) binding (as a spectroscopic probe) to these variants indicates 
different and probably mixed coordination geometries relative to [Co(II)(OH2/OH-)x]N 
(TRIL2WL23H)3n+, supporting the need for asymmetric site design in future work. 
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Protein design is a powerful approach for understanding metal sites in biology 
through reproduction of coordination environments and active site structures within a 
peptidic scaffold. Metal sites can efficiently catalyze many of the most complex and 
essential reactions in nature.1,2 The ability to reproduce these reactivities in a designed 
system is a true test of our knowledge of protein folding and how structure and function 
are related in metalloproteins. Relative to protein design in general, designing metal sites 
into proteins can be challenging due to the variability of metal ions in their oxidation 
states, ligand donor sets, and preferred geometries. However, many metal sites can also 
serve as spectroscopic tags to assist in characterization and assessment of the success of 
the design, thus speeding up the design process. Additionally, the variability and sheer 
catalytic power inherent in metal ions increases the variety of functions that can be 
achieved, which may allow for a wider range of novel metalloenzymes for commercial 
use. Since the first reports of designed proteins and metalloproteins began appearing over 
30 years ago, significant progress has been made in reproducing many native metal sites 
for a large variety of metals and metal cofactors.3–11 However, designed metalloproteins 
have often operated with a significant lack of catalytic efficiency relative to their 
designed counterparts.6,8,12 Now, there are several examples of functional metalloproteins 
with increasing enzymatic activities, suggesting that rivaling native metalloenzymes is a 
more accessible goal than ever. Reaching this point, however, has required many 
advances in metalloprotein (and non-metalloprotein) folding and design. Specifically, one 
must be able to design structural sites where a metal can impart thermodynamic stability, 
direct protein folding and/or stabilize non-preferred metal-binding geometries. These 
advances in understanding the balance between the protein scaffold stability and metal 
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ion coordination preferences often naturally lead to the design of catalytically active 
metal sites using a variety of approaches. The ultimate goal is to generate efficient 
metalloenzymes through a bottom up (de novo or “from scratch”) approach in which a 
primary sequence is chosen that folds into the predicted structure (requiring a deep 
understanding of protein folding, structure, and function). Other strategies, such as the 
redesign of native protein scaffolds, also provide new insight for metal-protein 
interactions. Through these complementary approaches, one might expect to be able to 
apply the insights gained throughout these studies to achieve one of the larger goals of 
the field: the design of novel metalloproteins with improved properties (stability, 
efficiency) and/or new catalytic activities. Such constructs, which are not found in nature, 
may be useful for a range of applications, including industrial processes where they could 
represent cheaper, more stable, and environmentally friendly alternatives to the current 
catalysts.  
 Metals in proteins have a wide range of functions that can be broadly classified 
into a few types: structural, catalytic, and electron transfer. Understanding how the 
protein matrix can fine-tune the properties of metal ions to affect such a variety of 
functions is an important question being actively addressed by protein design. The design 
of metalloproteins with electron transfer capabilities has been described.4,13 Here, I will 
focus on designed metalloproteins as they relate to structural and catalytic metal 
functions. After a discussion of general protein design approaches and scaffolds, I will 
described the design of structural metal sites (Section 2), highlighting the Pecoraro 
group’s work on the de novo design of metal-binding three-stranded coiled coils (3SCCs) 
(Section 2b), and discuss examples of functional de novo designed metalloenzymes 
(Sections 3 and 4). Section 3 will describe examples of designed enzymes which are not 
Zn(II)-dependent. Section 4 will describe the design of Zn(II)-binding proteins towards 
the generation of efficient hydrolytic zinc enzymes. 
 
1. Metalloprotein design approaches and scaffold choices 
 
Based on selection of the starting scaffold, metalloprotein design approaches can 
be categorized broadly into protein redesign or de novo (“from scratch” in its purest 
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form) protein design. Metalloprotein redesign encompasses a variety of approaches 
including redesign using non-metalloprotein scaffolds as a starting point and using 
existing metal sites and redesigning them into new metal sites with altered properties. De 
novo metalloprotein design, on the other hand, requires both design of a unique protein 
scaffold and incorporation of the metal site(s). Computational and/or empirical 
approaches to the design can be taken. Computational design of metalloproteins is 
currently limited due to the inherent variability in metal sites and a lack of suitable 
parameters to describe them (especially for the design of metal sites with non-preferred 
geometries), but nonetheless there are successes in this area.5,7,14,15 Empirical design can 
be less limiting but requires more knowledge about the templates being used and the 
design target. A combination of the two is often used. Further, proteins and 
metalloproteins can be designed combinatorially or rationally. Combinatorial design is 
typically used when little is known about the design goal and involves preparing a library 
of designs to sample, although it can be difficult to sample enough sequence variety.5 
Rational design is the ideal approach and allows more control over the outcome but also 
requires more in-depth knowledge of the structure and function. This approach has seen 
much success with the design of heme proteins.3 Often, a combination of rational and 
combinatorial approaches can be a very effective strategy. Here, I will focus on rationally 
designed metalloproteins. 
 
a) Protein redesign 
 
One can take a redesign approach by beginning with a native protein scaffold and 
incorporating a novel metal site, through introduction of the necessary ligands into a non-
metalloprotein (or into a new location of an existing metalloprotein), redesign of an 
existing metal site, or incorporation of a metal cofactor or complex. Evolved proteins 
tend to be fairly stable and can handle the multiple mutations required to engineer a metal 
site. If chosen correctly, they can be easily obtained in high yield and are already well 
characterized. It can even be argued that nature uses this approach. Although there are a 
large number of characterized sequences and structures available, there are only ~1000 
unique protein folds known and often, many different types of proteins with diverse 
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functions use a single protein fold (an important example of this is the Greek key β-barrel 
fold).5 It is possible that nature may only use a small number of thermodynamically 
stable scaffolds to design repeatedly many proteins with diverse active site structures and 
functions. Relative to de novo design, this approach can currently offer a wider variety of 
potential scaffolds, as there are relatively few robust de novo designed scaffolds (Section 
1c). On the other hand, this could also prove to be a drawback as it may be difficult to 
divulge hidden structural features in complex native proteins. Nevertheless, there is much 
that has been and will continue to be learned from the redesign of existing 
metalloproteins. Although my focus is on de novo designed proteins, there are several 
recent and impressive reports of redesigned functional metalloproteins14,16–25 and many 
others that have been reviewed.3,5,7,9,26–30 
 
b) De novo protein design 
 
The de novo, or in its purest form, “from scratch”, approach to metalloprotein 
design is to build a well-folded protein structure from a primary sequence not directly 
related to that of any natural protein and subsequently engineer a metal-binding site.10 
The basis of de novo design usually involves a minimization or simplification of protein 
structure.31,32 One of the goals is to attain a minimal specific structure that removes much 
of the excess of a native protein but retains sufficient complexity for protein-like 
functions. The main advantage of this approach is that it eliminates most of the 
convoluted behaviors that make characterizing many native metalloproteins difficult. It is 
likely that this simplified approach to characterizing metal binding and function may 
uncover otherwise hidden subtleties in structure-function relationships. With a deeper 
understanding of the necessary features, increasing amounts of complexity can then be 
incorporated, as deemed necessary, into these minimal designs. Ultimately, careful 
analyses of de novo designed metalloproteins, combined with the information learned 
from redesign endeavors, should lead to the ability to prepare de novo designed metal-
based biocatalysts for a variety of desired functions not necessarily found in nature and 
for a variety of applications. 
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c) Scaffolds for designing metal-binding sites 
 
Design of a metal-binding site, regardless of the approach, first requires a stable 
protein scaffold into which mutations can be made to incorporate ligands for metal (or 
metal cofactor) binding. For protein redesign, the scaffold is typically chosen based on 
the goal of the design and the properties of the native scaffold and nature provides many 
existing scaffolds to choose from.5 A variety of approaches can be taken including 
engineering a metal- or metal cofactor-binding site into a non-metalloprotein3,7,14,16,17,26–
28, redesigning an existing metal-binding site19,33–35, removing and inserting entire loop 
sequences containing the desired metal-binding site5,9,20, and generating multimeric 
protein structures with metal-mediated protein interfaces.18,36–39 
Far fewer de novo designed scaffold choices have been prepared to date, which 
limits the range of metalloprotein environments that may be examined. Ultimately, one 
goal of de novo design would be to expand this repertoire to include at least as many, if 
not more, scaffolds than those provided by nature. Initial attempts at de novo protein 
design lead to structures that formed molten globules, but now there are a number of 
successful examples of small uniquely folded proteins. Hydrophobicity provides a strong 
driving force for folding but many more subtle features also need to be incorporated for 
both stability and specificity such as hydrogen bonding, electrostatics, side-chain 
 
Figure 1-1. Helical wheel diagrams for parallel (a) two-, (b) three-, and (c) four-
stranded coiled coils. Figure reproduced from ref. 53. 
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packing, and conformational preferences. Most de novo designed proteins consist of α-
helices and are either coiled coil structures made up of self-assembling peptides or α-
helical bundles made up of helix-loop-helix motifs.8,10,40 The fact that α-helices have 
intrastrand interactions with residues that are close in the primary sequence to stabilize 
their structures is one aspect (as opposed to interstrand hydrogen bonding found in β-
sheets) that made them an attractive initial target for design.  
Hodges and coworkers pioneered the de novo design of α-helical coiled coils.10,41–
44 The α-helical coiled coil is made up of a bundle of parallel or antiparallel amphipathic 
α-helices with a left-handed superhelical twist.45–48 The primary sequence contains a 
seven residue repeating sequence (the heptad repeat), with positions designated a-g. The 
residues in the a and d positions are directed towards the interior of the structure and tend 
to be hydrophobic while hydrophilic residues in the remaining positions are involved in 
electrostatic interactions. The association of hydrophobic a and d residues provides part 
of the driving force for assembly of the coiled coil. Helix-inducing residues, such as Ala, 
may be placed in the c position. Figure 1-1 illustrates these interactions for parallel two-, 
three-, and four-stranded coiled coils (XSCCs where X = 2, 3, or 4). Specific oligomers 
of α-helices can be attained through the rational design of core-packing interactions 
(typically by varying the size of the hydrophobic residues) and surface electrostatics 
(which also contribute to stabilization of parallel or antiparallel configurations of coiled 
coils).32,42,49–52 The heptad repeat approach is a highly versatile method that has yielded 
many successful designed metalloproteins (Figure 1-2a, b).7,53–70 In particular, the 
Pecoraro group has designed the TRI family of peptides, which are α-helical coiled coils 
that fold into specific aggregates depending on pH, peptide length, and sequence 
composition (these will be described in detail in Section 2b).53,63,71,72 
Another structure type extensively explored in protein design is the α-helical 
bundle. Although often designed based on coiled coils, α-helical bundles can be 
structurally different in that the helices gradually diverge from a point near one end of the 
bundle.73,74 The most common are the four-helix bundles and one of the earliest examples 
of a designed four-helix bundle is α4.31,75 This small protein was prepared by taking short 
helical sequences that could self-associate into a tetramer, adding hairpin loops to make a 
dimer of helix-loop-helix motifs, and finally incorporating a third loop to create a single 
 7 
primary sequence. Although this bundle adopted a folded, globular conformation in 
aqueous solution, the core was too conformationally flexible (it contained only Leu 
residues) leading it to exhibit some molten globule-like characteristics rather than 
assuming a single native state. Insertion of metal-binding residues to create a ZnHis3 site 
did help induce a more native-like state into α4.49,76 Now, there are many examples of 
well-folded α-helical bundles that adopt a single native state due to the incorporation of a 
variety of more specific interactions both in the hydrophobic core and on the hydrophilic 
surface.10,74,77 There are also examples where metal sites are engineered into α-helical 
bundles.15,76,78–80 The Pecoraro group has recently reported the incorporation of a heavy 
metal-binding Cys3 site into a three-helix α-helical bundle (α3D, Figure 1-2c) that was 
originally designed based on CoilSer (CS, a de novo designed 3SCC, Table 1-1, Figure 
1-2a, b).74,79 DeGrado and coworkers have reported an extensive amount of work on the 
 
 
Figure 1-2. Structures of representative de novo designed α-helical coiled coils 
and bundles. (a) X-ray structure of a 3SCC, CoilSer, generated from pdb 
1COS50, (b) X-ray structure of a metal-bound 3SCC, [As(III)]S(CSL9C)3, 
generated from pdb 2JGO68 with side-on view (top) and top-down view (bottom); 
As-S metal-ligand bond distances all 2.3 Å, (c) NMR structure of a three-helix α-
helical bundle protein generated from pdb 2A3D74, (d) X-ray structure of a 
dinuclear metal site in a designed four-helix bundle protein (diZn(II)-DF1) 
generated from pdb 1EC515 with side-on full view (top) and close-up view of 
metal site (bottom); All metal-ligand bond distances are in the range 1.8-2.1 Å. 
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dimetal-containing four-helix bundle Due Ferri (DF, Figure 1-2d, to be discussed in detail 
in Section 3a).6,15,81–84 
Although the de novo design of proteins has been dominated by preparation of α-
helical coiled coils and bundles, there has also been substantial effort directed towards the 
formation of β-sheet structures. This is relatively challenging, not only because of the 
need to create more interstrand interactions between residues well-separated in sequence, 
but because there are issues with aggregation, overall stability, folding cooperativity, and 
challenges in designing turn sequences. Residues that are bulky and hydrophobic, such as 
Tyr, Phe, Thr, Ile, Val, and Trp, seem to have a higher propensity towards the formation 
of β-sheet structures. Despite these challenges, there are several successes in the design 
of β-sheet structures85–90 and related scaffolds including mixed α/β structures91–94, γ 
turns95, β-hairpin peptides96–99, and small peptides with loop region metal clusters.100,101 
There is also limited success in the de novo design of β-structured scaffolds for functional 
metalloproteins; the design of a redox-active rubredoxin mimic is an example of one of 
these rare β-sheet metalloproteins.102 
Table 1-1. CoilSer (CS) and TRI peptide family sequences used in these studies. 
Peptide           a b c d e f g    
CoilSer (CS) Ac-E WEALEKK  LAALESK  LQALEKK  LEALEHG        -NH2 
CSL9C Ac-E WEALEKK  CAALESK  LQALEKK  LEALEHG        -NH2 
CSL19C Ac-E WEALEKK  LAALESK  LQACEKK  LEALEHG        -NH2 
CSL9PenL23H Ac-E WEALEKK  PenAALESK LQALEKK HEALEHG      -NH2 
TRI Ac-G LKALEEK   LKALEEK  LKALEEK  LKALEEK        G-NH2 
TRIL9C Ac-G LKALEEK   CKALEEK  LKALEEK  LKALEEK        G-NH2 
TRIL12C Ac-G LKALEEK   LKACEEK  LKALEEK  LKALEEK        G-NH2 
TRIL16C Ac-G LKALEEK   LKALEEK  CKALEEK  LKALEEK        G-NH2 
TRIL12CL16C Ac-G LKALEEK   LKACEEK  CKALEEK  LKALEEK        G-NH2 
TRIL2WL9C Ac-G WKALEEK  CKALEEK  LKALEEK  LKALEEK        G-NH2 
TRIL2WL23C Ac-G WKALEEK  LKALEEK  LKALEEK  CKALEEK        G-NH2 
TRIL23H Ac-G LKALEEK   LKALEEK  LKALEEK  HKALEEK        G-NH2 
TRIL2WL23H Ac-G WKALEEK  LKALEEK  LKALEEK  HKALEEK        G-NH2 
TRIL9CL23H Ac-G LKALEEK   CKALEEK  LKALEEK  HKALEEK        G-NH2 
Baby Ac-G LKALEEK   LKALEEK  LKALEEK                              G-NH2 
BabyL9C Ac-G LKALEEK   CKALEEK  LKALEEK                             G-NH2 
BabyL12C Ac-G LKALEEK   LKACEEK  LKALEEK                             G-NH2 
Grand Ac-G LKALEEK   LKALEEK  LKALEEK  (LKALEEK)2     G-NH2 





2. Designing structural metal sites 
 
 Many metal ions play a structural role in their protein environments. They can act 
to simply stabilize a structure by inducing or assisting folding or as switches for 
converting one conformation into another (for example, to regulate activity). These are 
most commonly represented by Zn(II)-thiolate sites (as in zinc fingers which are typically 
comprised of ZnCys2His2 coordination environments, and will be discussed in more 
detail in Section 4) and calcium sites (calmodulin), although others exist.103–105 There are 
examples of designed metal-binding sites in which the metal plays a structural role.53,64,70 
In addition to describing the Pecoraro group’s work involving heavy metal binding, 
particularly with Hg(II) to thiol sites in α-helical coiled coils in Section 2b, I will briefly 
highlight other examples and recent approaches to the design of structural metal-binding 
sites in proteins. 
 
a) Metal-assisted and metal-induced folding in α-helices and α-helical coiled coils  
 
In the field of metalloprotein design, there are many examples in which metal ion-
assisted folding and self-assembly of α-helical coiled coils generates well-defined 
secondary and tertiary structures.64,69,106–111 Although these studies are extensive, here I 
will focus on those which are relevant to the most recent studies in the context of this 
chapter. Further discussion on those designs which are Zn(II)-dependent will be provided 
in Section 4a. Figure 1-3 provides models of some of the important constructs described 
below. 
Ghadiri et al. were among the first to exploit the design of metal-binding sites in 
peptides to promote the formation of α-helices112,113 and coiled coils.107,114 They designed 
a 17-mer peptide (Ac-AEAAAKEAAAKX1AAAX2A-CONH2 where X1 = His and X2 = 
His or Cys) which could bind Cd(II), Cu(II), Ni(II), and Zn(II), all with an enhancement 
in α-helicity from 54% to ~90%. Using the His/His version of this peptide, binding of an 
exchange-inert metal complex, [Ru(NH3)5(OH2)]2+, leads to the formation of a 
macrocyclic complex, cis-[Ru(NH3)4(His)2peptide]3+, with 80% α-helical content. The 
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group has also designed a 15-mer amphiphilic peptide with a 2,2’-bipyridine moiety at 
the N-terminus which, upon binding Ni(II), Co(II), or Ru(II), self-assembles to form a 
3SCC with > 70% α-helical content.107 This construct was also used as a template for 
incorporation of a Cu(II)(His)3 site to form a heterodinuclear three-helix construct 
(Figure 1-3a).114 Further, a stable parallel four-helix bundle metalloprotein is obtained by 
incorporating another 15-residue amphiphilic peptide with a pyridyl group at the N-
terminus and binding Ru(II).115 
Along similar lines, the Ogawa group has also reported the use of metal-binding 
sites to generate α-helical bundles. Kharenko et al. designed a 32-mer peptide C16C19-
GGY (Ac-K(IEALEGK)2(CEACEGK)(IEALEGK)GGY-CONH2), which has Cys 
residues in adjacent a and d positions of one of the heptads, resembling the Cys-X-X-Cys 
motif found in rubredoxin. Upon binding Cd(II), the apo-peptide went from a random 
coil to a 2SCC containing a single Cd(II) ion (Figure 1-3b).13,54 Interestingly, when Cu(I) 
is bound to the same peptide, a four-helix bundle metalloprotein containing a tetranuclear 
Cu4S4 cofactor is generated (Figure 1-3c).116 Further, upon binding Pt(en)(NO3)2 to the 
 
Figure 1-3. Examples of metal-stabilized α-helical structures described in this 
section. (a) Computer-generated model of the parallel three-helix bundle 
Cu(II)Ru(II) metalloprotein with full side-on view (left) and close-up views of 
each metal site (right). Figure reproduced from ref. 114. (b) Energy-minimized 
computer model of the Cd(II)-bridged C16C19 peptide dimer (2SCC) with Cd(II) 
bound in a tetrahedral geometry. Figure reproduced from ref. 13. (c) Computer-
generated model of the tetrameric Cu(I)-C16C19-GGY metalloprotein (4SCC). 
Figure reproduced from ref. 13. (d) Model of the Ni(II)-His6 complex of IZ-3adH 
(3SCC) with full side-on view (top) and a bottom-up view from the C-termini 
(bottom). Figure reproduced from ref. 110.  
!
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30-residue peptide AQ-Pal14Pal21 (which contains two 4-pyridylalanine, or Pal, binding 
residues on its surface and exists as a 2SCC in its apo form)  results in a significant 
conformational change to a metal-bridged four-helix bundle.108 
Tanaka and coworkers have used the heptad repeat approach to design a parallel 
3SCC peptide (in the presence of bound metal ions) with the sequence YGG(IEKKIEA)4 
called IZ. The peptide IZ-3aH was generated by substitution of an isoleucine residue on 
the third heptad with a His and IZ-3adH could be generated with two His 
substitutions.110,117 While this sequence showed only random coil-like secondary 
structure in solution, it was induced to fold into a 3SCC in the presence of metal ions 
such as Cu(II), Zn(II), Co(II), and Ni(II) (Figure 1-3d). Metal binding could be followed 
by monitoring the folding with circular dichroism (CD) as a function of the metal 
concentration, yielding dissociation constants in the low µM range. Substituting Cys 
residues into the IZ peptides also yields metal-binding sites for Cd(II) and Hg(II).111 
Recently, the group reported a study in which they fused the IZ-3adH peptide to another 
functional protein (a derivative of a naturally occurring DNA-binding domain) to create a 
metal ion-controlled DNA-binding protein which could modulate hydrolysis of the DNA 
site and inhibit RNA transcription by T7 RNA polymerase.118 
As will be discussed in Section 2b, the Pecoraro group has shown that heavy 
metal-thiolate binding can also be used to induce and mediate the folding of 2- and 
3SCCs. 
Further, as will be discussed in Section 3b, the Ball group has exploited the metal-
induced α-helicity of 2SCCs and the inherent properties of coiled coil structures to design 
dirhodium-based catalysts for a variety of roles relevant to enzymatic function. 
 
b) Binding of Hg(II) to the TRI family of α-helical coiled coils  
 
The Pecoraro group’s work is based on the TRI family of de novo designed 
peptides71,72 for which the parent sequence, Ac-G(LKALEEK)nG-NH2, is based on that 
of CoilSer50,119 and consists of four heptad repeats. This heptad repeat sequence results in 
amphipathic α-helices with all Leu residues in the a and d positions on the hydrophobic 
face, Ala in the c position, and Lys and Glu residues in most of the remaining positions 
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on the hydrophilic face. In aqueous solution, the hydrophobic residues aggregate at low 
pH to form a 2SCC and as the pH is raised above 5.5, salt bridge interactions between 
Lys and Glu at the interfaces between helices stabilize a parallel 3SCC. The a and d 
residues point towards the interior of the coiled coil to form the hydrophobic core. 
Substitution of these Leu residues with residues such as Cys or His yields metal-binding 
sites. Figures 1-4 and 1-5 display the crystal structures of apo-(CSL9C)3n- (a site) and 
apo-(CSL19C)3n- (d site), respectively.67 Peptide sequences are given in Table 1-1. These 
structures demonstrate the differences between these types of sites in the absence of 
metal. For the a site, the Cys side chains show alternate conformations with the 
predominant form preorganized for metal binding. Comparison of this apo-peptide with 
the corresponding metal-bound version, [As(III)]S(CSL9C)368 ([As(III)]S is used to 
 
 
Figure 1-4. Ribbon diagrams of the X-ray crystal structure of apo-(CSL9C)3n- 
showing the orientation of the Cys ligands. The Cys side chains are shown as red 
sticks with thiol groups colored yellow. Top-down views from the N-termini show 
(a) the orientation of the major conformer with all Cys side chains pointing 
towards the interior of the trimer and (b) the minor conformer with Cys side 
chains pointing towards the helical interface. Side-on views further demonstrate 
the flexibility of this site. (c) In the major conformer, the thiol groups point 
towards the N-termini and (d) in the minor conformer, the thiol groups point 
towards the C-termini. Figure reproduced from ref. 67.  
!
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indicate that As(III) is bound at the Cys3 site), suggests only minor changes in the Cys 
residue geometries where they are slightly more constrained with metal binding. The d 
site residues, on the other hand, exist in a single conformation different than those 
observed in CSL9C, resulting in a larger cavity which can accommodate metals with 
larger ionic radii, such as Pb(II). 
The Pecoraro group has also shown that non-natural amino acids can be used for 
metal recognition. Specifically, Penicillamine (Pen) can be used to increase steric bulk 
directly around the metal-binding pocket, thus enforcing lower coordination geometries 
than may otherwise be observed.66,120,121 Further, alternate chirality amino acids have 
been shown to create smaller metal-binding pockets when placed in the Leu layer above 
the metal-binding site.122 Moreover, placement of a D-amino acid ligand in the metal-
binding Leu layer alters the ligand environment.123 Specifically, Peacock et al. reported 
the crystal structures of apo-(CSL16Pen)3n- and apo-(CSL16DPen)3n-, which demonstrate 
that incorporation of a D-amino acid ligand results in a metal binding site that is not 
preorganized for metal binding (Figure 1-6). This work provides a structural explanation 
for the relatively poor binding of Cd(II) to D-Pen as compared to L-Pen. 
 
 
Figure 1-5. Ribbon diagrams of the X-ray crystal structure of apo-(CSL19C)3n- 
showing the orientation of the Cys ligands. The Cys side chains are shown as red 
sticks with thiol groups colored yellow. (a) The top-down view from the N-
termini shows that two of the Cys ligands point towards the interior of the coiled 
coil and the third toward the helical interface. (b) The side-on view demonstrates 
that two thiol groups point towards the C-termini while the third is almost 
perpendicular to the helical axis. Figure reproduced from ref. 67.  
!
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In theory, the three-fold symmetric nature of the coiled coils can allow for the 
preparation of most metal geometries within its scaffold (Figure 1-7). With substitution 
of a single Leu layer, trigonal planar or trigonal pyramidal structures can be achieved 
depending on the stereochemical preference of the metal. A tetrahedral geometry may be 
observed with the inclusion of a solvent molecule and with two solvent molecules, a 
trigonal bipyramidal metal site might be observed. Substituting two adjacent Leu layers 
and inserting the appropriate metal may yield an octahedral site (Suzuki et al. have 
 
 
Figure 1-6. Ribbon diagrams of the X-ray crystal structures of apo-
(CSL16Pen)3n- and apo-(CSL16DPen)3n- displaying the orientation of the Pen side 
chain. The L- (purple) and D-Pen (blue) side chains are shown in stick form with 
the thiol group colored orange. Side-on views show (a) L-Pen residues oriented 
toward the N-termini and (b) D-Pen residues oriented toward the C-termini. Top-
down stereo views from the N-termini are shown and display (c) L-Pen residues 
oriented toward the interior of the coiled coil and (b) D-Pen residues oriented 
toward the helical interface. Figure reproduced from ref. 123.  
!
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reported an α-helical trimer with two adjacent His3 sites which can bind Ni(II), Zn(II), 
and Co(II) in octahedral geometries110). Further, a linear metal-binding site may be 
attained by either lowering the pH to stabilize the 2SCC, incorporating the appropriate 
metal and metal:peptide ratios (as will be described for Hg(II)), or at lower pH’s in the 
presence of a 3SCC (where the third protein ligand present is not bound), as 
demonstrated in the structure of [Hg(II)]S[Zn(II)(OH2/OH-)]N(CSL9PenL23H)3n+, which I 
will describe in Chapter 2 (the nomenclature of this complex now accounts for a 
coordinated solvent molecule to the Zn(II) ion: if the pH conditions are such that the 
solvent may occur as both H2O and OH- then OH2/OH- will be used). Therefore, using a 
three-fold symmetric coiled coil as a scaffold should allow for an extensive range of 
different metal-binding structures for a variety of metals and amino acid ligands within 
the same relative protein environment. 
 
 
Figure 1-7. PyMOL264 models of possible metal-binding geometries in a 3SCC. 
The metal-binding ligands are Cys residues and the metal is colored purple. (a) 
side-on view (top) and top-down view (bottom) of two-coordinate or linear 
geometry, (b) side-on view (top) and top-down view (bottom) of three-coordinate 
trigonal planar geometry, c) side-on view (top) and top-down view (bottom) of 
four-coordinate tetrahedral geometry, (d) side-on view of five-coordinate trigonal 
bipyramidal geometry, and (e) side-on view of six-coordinate octahedral metal 




Until recently, most of the Pecoraro group’s work on this system has focused on 
the preparation of thiolato coordination environments for metals such as Hg(II), Cd(II), 
Pb(II), As(III) and Bi(III) with the goal of understanding how heavy metals are 
coordinated in biological environments.53,59–62,67,68,71,72,120,121,124–129 Although the toxic 
effects of these metals are well known, the causes are often not well understood due to a 
lack of suitable models, especially in the case of Hg(II).63 Preparing thiophilic metal-
binding sites in the TRI family of proteins has yielded not only a better understanding of 
how heavy metals are coordinated in native metalloproteins, but also information on how 
to selectively control these coordination environments. Previous reviews have discussed 
Hg(II) and Cd(II) binding in some detail53,59,63,65, but here I will focus on describing 
Hg(II) binding as a means to achieve a structurally stabilizing metal-binding site in a 
3SCC. 
The Pecoraro group’s protein design studies began by examining Hg(II) binding 
to peptides such as TRIL16C and TRIL12C, where Leu has been substituted for Cys in 
 
 
Figure 1-8. Species present at different TRIL9C/Hg(II) ratios and pH values. 
Figure reproduced from ref. 265.  
!
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an a site and a d site, respectively (sequences of the peptides to be discussed can be found 
in Table 1-1). As the group has shown with crystal structures of apo-(CSL9C)3n- and apo-
(CSL19C)3n- (Figures 1-4 and 1-5), and, as will be  described in terms of solution studies 
below, this seemingly slight shift in sequence position is significant for metal binding. To 
describe the binding of Hg(II) to these peptides, a variety of conditions must be 
considered (Figure 1-8). At low pH (< 5.5), 2SCCs containing a linearly-bound Hg(II) 
ion are formed. It is well known that this is the preferred geometry of Hg(II).130,131 More 
interestingly, three distinct behaviors are observed at higher pH. When the peptide 
monomer (single α-helix) to Hg(II) ratio is 2:1, 2SCCs with two-coordinate Hg(II) are 
formed for both peptides, indicating that the Hg(II)-binding preference dominates the 
preferred bundle aggregation state. When this ratio is increased to 3:1, and in the pH 
range of 5.5-7, both peptides contain two-coordinate Hg(II) within a 3SCC, simply 
suggesting that the third Cys remains protonated and unbound. Finally, for TRIL16C 
above pH 8.6 and TRIL12C above pH 9.5, fully three-coordinate trigonal planar Hg(II) is 
obtained. Based on an equilibrium between two- and three-coordinate Hg(II) within the 
3SCC, the pKa for deprotonation of the third Cys can be determined and is 7.8 for the a 
site and 8.5 for the d site, indicating that metal binding to Cys residues is dependent on 
the a vs d substitution pattern. Importantly, this represents the first peptidic system to 
bind Hg(II) as a trigonal thiolato complex in aqueous solution and is an excellent model 
for the regulatory protein, MerR.71,72,132 I have also reported the crystal structure of the 
complex (to be described in detail in Chapter 2), [Hg(II)]S[Zn(II)(OH2/OH-)]N 
(CSL9PenL23H)3n+ (pH 8.5), which contains a trigonal HgS3 site in one trimer of the 
asymmetric unit (ASU) and a T-shaped Hg(II) site in the other70, crystallographically 
confirming the spectroscopic data. Through preparation of dual-cysteine peptides (in 
which two adjacent layers of Leu are substituted), the Pecoraro group was able to 
generate exclusively four-coordinate HgS4 with the sequence TRIL12CL16C, 
representing a model of Hg(II)-substituted rubredoxin.133,134 Extensive spectroscopic 
analysis of this designed system using numerous techniques for probing the metal 
coordination over a broad range of timescales (including UV-Visible characterization, 
199Hg NMR, 199mHg perturbed angular correlation (PAC, where 199mHg is a metastable 
isotope of 199Hg which emits two successive γ rays upon its decay) and X-ray Absorption 
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(XAS) spectroscopies) provides a summary of the properties expected for homoleptic 
Hg(II)-thiolates in biological systems (Table 1-2).63 
A deeper analysis of the relationship between the peptide self-association affinity 
and Hg(II) (and Cd(II)) binding with a series of peptides demonstrated a linear free 
energy correlation with metal binding (Figure 1-9).  In the case of Hg(II), this helped 
confirm the notion that trigonal Hg(II) complexation is a direct result of the designed 
peptide recognition. Further, attempts to form heterotrimeric complexes between 
TRIL2WL9C and TRIL2WL23C and Hg(II) did not succeed, demonstrating that control 
over orientation of the peptides is retained in the face of metal binding. The self-
Table 1-2. Spectroscopic values for [Hg(II)]S(TRILXC)Xn- complexes. 





Linear 2-coordinate 240 (2700)d - 2.32d -844e 1.53, 0.13e 
Trigonal 3-coordinate a 
site 
247 (19200)f 7.6 ± 0.2g 2.44f, 2.23l -185e 1.16, 0.25e 
265 (11900)f     
295 (5800)f     
Trigonal 3-coordinate d 
site 
230 (21300)h 8.5 ± 0.2h 2.44h -316i - 
247 (15000)h     
297 (5500)h     
Linear 2-coordinate 
within a 3SCC 247 (2000)
j - 2.29, 2.13, 3.06m -908
e 1.56, 0.23e 
Tetrahedral 4-coordinate 230 (8100)k - - -500k - 
289 (7100)k     
a. !λ given in nm and Δε given as M-1 cm-1. 
b. Average Hg-S EXAFS bond lengths. 
c. νQ given in GHz and η is a unitless quantity. 
d. Data for TRIL16C from ref. 72. 
e. Data for TRIL9C from ref. 265. 
f. Data for TRIL16C from ref. 127. 
g. Data for TRIL9C from ref. 125. 
h. Data for TRIL12C from ref. 127. 
i. Data for TRIL19C from ref. 265. 
j. Data for TRIL12C from ref. 266. 
k. Data for TRIL12CL16C from ref. 134. 
l. Data from the crystal structure of [Hg(II)]S[Zn(II)(OH2/OH-)]N(CSL9PenL23H)3n+ 
for the trigonal HgS3 site. Average of the three Hg-S bonds to Pen, 2.21, 2.07, and 
2.41 Å70. 
m.  Data from the crystal structure of [Hg(II)]S[Zn(II)(OH2/OH-)]N(CSL9PenL23H)3n+ 
for the T-shaped Hg(II) site70. 
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association affinity as it relates to Hg(II) binding can be examined more deeply by 
considering the peptides used in the analysis. This affinity can be increased by increasing 
the hydrophobic contacts in the coiled coil by incorporating an extra heptad (this 
sequence is called Grand instead of TRI) and can likewise be decreased by either 
removing a heptad (to generate a sequence named Baby) or by substituting less 
hydrophobic residues for Leu around the metal site (such as Val, Ala, and Gly). At the 
conditions under which these peptides are typically studied (low µM concentrations), 
Baby exists as random coils in solution, TRI is folded into an α-helical coiled coil, and 
Grand forms an even tighter coiled coil complex. Typically, the α-helical character 
correlates with association of the coiled coils (amphipathic α-helices will not be well 
folded in aqueous solution if their hydrophobic faces are exposed), therefore, by 
monitoring the signal at 222 nm using CD, one can determine how well folded a given 
peptide is. Fitting a plot of the signal at 222 nm vs increasing concentration of guanidine 
hydrochloride (GuHCl) denaturant can yield the free energy of folding for the complex. 
As expected, when Leu residues are replaced with smaller and less hydrophobic residues, 
 
 
Figure 1-9. Linear-free energy correlation between folding preferences of the 
peptides in the absence of metal to the binding of a third strand of peptide to a 
divalent Hg(II)S2 species. Figure reproduced from ref. 267.  
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the peptide association becomes weaker (~1-2 kcal mol-1 per residue per peptide). This 
effect is directly correlated with the affinity of Hg(II) (and Cd(II)) for each of the 
peptides, demonstrating that it is not the metal’s geometric preference controlling the 
association of the coiled coils, but the free energy of folding of the peptides. This 
conclusion supports the theory that in biological systems, the surrounding protein matrix 
mediates folding and stabilization of unusual metal sites.  
Trigonal planar Hg(II) complexes could be obtained in all of these designs, but 
the kinetics of metal binding is different and can again be related to the self-association 
of the peptides. Above I described how a heptad could be added to or removed from TRI 
to produce the Grand and Baby sequences, respectively. While TRI is well folded at a 
10 µM concentration, BabyL9C has only 20% helicity (% helicity is the measured molar 
ellipticity as a fraction of the maximum ellipticity for a fully α-helical complex of the 
same size). However, in the presence of Hg(II), BabyL9C could still form a stabilized 
3SCC. Initially, this challenged the notion that a preorganized site is necessary to 
stabilize alternate coordination geometries around metals in designed systems. To this 
end, a thermodynamic model was derived to explain how small, unstructured peptides 
could ultimately stabillize a [Hg(II)(SR)3]- site.53,126 First, a 2SCC is nucleated by the 
addition of Hg(II) to a solution of peptide because two-coordinate linear Hg(II) binding 
to thiolates is a highly favored process. When a third equivalent of peptide monomer is 
added, peptide-peptide interactions overwhelm the coordination preference of the metal 
to give a 3SCC final structure. Kinetic studies examining BabyL9C and Hg(II) binding 
showed that the initial binding and formation of a [Hg(II)]S(BabyL9C)2 site in a 2SCC is 
very fast while formation of [Hg(II)]S(BabyL9C)2(H-BabyL9C) with addition of more 
peptide is rate-limiting. This step may be described by the stepwise aggregation-
deprotonation (StepAD) model in which the third helix binds to the 2SCC in either a 
parallel (productive complex) or antiparallel fashion (unproductive) and every time 
antiparallel binding occurs, the helix must first dissociate then reassociate in a parallel 
manner (Figure 1-10). This is followed by deprotonation of the third Cys residue at the 
appropriate pH to form a fully trigonal [Hg(II)]S(BabyL9C)3- complex. The pKa for 
deprotonation depends on the location of Cys in the sequence, but is independent of the 
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length of the sequence (this pKa is 7.8 for both a site peptides, TRIL9C and BabyL9C 
while for TRIL12C and BabyL12C, both d site peptides, it is 8.4). 
The case of Hg(II) binding to the Baby peptide is particularly informative as to 
how metals can stabilize protein folds. Since Baby exists at µM concentrations as 
unassociated and unfolded individual peptides, addition of metal is essential for proper 
folding. Stopped-flow kinetic analysis revealed that under all of these conditions, Hg(II) 
complexation to two thiolates first generates the [Hg(II)]S(Baby)2 species, which then 
acts as a nucleating agent for the third strand of the bundle to associate.126 Thus, it can be 
concluded that the presence of the metal site stabilizes the preferred fold (3SCC) by 
initiating the assembly of the bundle through the non-preferred initial 2SCC. Once the 
system begins to fold by forming the 2SCC, it subsequently adopts the preprogramed 
3SCC structure. This example illustrates that a metal site may induce a desired protein 
fold by stabilizing an early folding intermediate even though the final, desired fold leads 
to an undesired coordination environment for the metal. This work clearly demonstrates 
 
 
Figure 1-10. Stepwise aggregation-deprotonation (StepAD) mechanism for the 
encapsulation of Hg(II) by the 3SCC, (BabyL9C)3n-. Hg(II) reacts in a fast step to 
form [Hg(II)]S(BabyL9C)2. Formation of [Hg(II)]S(BabyL9C)2(H-BabyL9C) is 
the rate-limiting association and, depending on pH, rapidly converts to 
[Hg(II)]S(BabyL9C)3-. Figure reproduced from ref. 126.  
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the intricate balance and interplay between metal-binding preferences and protein 
folding. 
 The difference in the observed pKa values for Hg(II) binding to BabyL9C and 
BabyL12C prompts a further examination of the difference between a and d sites. A 
comparison between Hg(II)-induced folding in BabyL9C and BabyL12C revealed not 
only different pKa’s but also a lower extinction coefficient (for the ligand-to-metal charge 
transfer transition representing Hg(II)-thiolate bond formation) and Hg(II)-binding 
affinity and a lower free energy change for Hg(II) complex formation with BabyL12C. A 
concentration-dependence study of coiled coil association revealed a higher self-
association affinity for the a site peptide. Kinetic studies revealed a faster rate for Hg(II) 
binding to BabyL12C, likely due to this lower self-association preference (more 
monomers in solution can lead to more rapid nucleation). Modeling studies demonstrated 
the Cys conformation found in d site peptides is less favorable than that in a sites because 
the d site amino acid must twist from its normal position in the apo-bundle and orient 
 
 
Figure 1-11. Possible mechanisms for insertion of Hg(II) into the folded peptides. 
Figure reproduced from ref. 53.  
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more towards the core, whereas the a site residue resembles a more preorganized metal-
binding site. As discussed earlier in this section, these modeling studies have now been 
confirmed crystallographically with apo structures of CSL9C and CSL19C.67  
Further kinetic studies performed on TRIL9C and TRIL12C showed the same a 
vs d site pattern where Hg(II) insertion into the d site was faster than the a site. However, 
the mechanism of metal insertion into these prefolded peptides must be different than that 
derived for the unfolded peptides. There are two possibilities (Figure 1-11); one is the 
breathing mechanism in which the 3SCC may open up and allow the metal ion to insert 
and the other is the dissociative mechanism, which is similar to the StepAD mechanism, 
in which the third helix must first dissociate and then reassociate in the proper orientation 
to result in a productive 3SCC. The observed biphasic behavior of Hg(II) encapsulation 
can be most easily rationalized with the dissociative mechanism; if some are misfolded 
then the step where a peptide must be lost from the 3SCC and then reassociated in the 
correct manner would represent a slower second phase. However, the breathing 
mechanism cannot be ruled out since the same pattern as was observed for Baby is 
observed for TRI, where the kinetics for d site insertion is faster. More experiments are 
needed to rationalize these mechanisms; however, some general conclusions for the field 
of protein design can be drawn from this work. One important observation is that a highly 
stable apo-protein may not be kinetically optimal for metal binding (another example 
where this is the case is described in the following Section 3a). It is likely that nature 
makes compromises between rapid kinetic transfer and high metal ion-protein affinity. 
Further, highly stable scaffolds are not necessarily required to enforce a non-preferred 
metal coordination environment (often required for functional metalloproteins) and may 
actually be detrimental to the kinetics of metal ion insertion. 
 
3. Designing functional metalloproteins 
 
The ultimate goal of metalloprotein design is to be able to prepare metalloproteins 
that can efficiently catalyze virtually any reaction as native enzymes can do for biological 
reactions in mild, aqueous environments with as-yet unrivalled speed and specificity. 
Attempts at generating catalytic proteins and metalloproteins came soon after the first 
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protein design papers, but until recently most have demonstrated rather poor efficiencies 
(if they have any reactivity at all). Many of the attempts at designing enzymes have been 
reviewed7,8 and here I will focus on some of the most recent examples of functional de 
novo designed metalloproteins. In this section, I will exclude those functional examples 
which are Zn(II)-dependent. Given that the focus of my doctoral work is on the design of 
hydrolytic Zn(II) enzymes, Section 4 will describe in more detail the chemistry of Zn(II), 
the design of Zn(II)-binding sites and, ultimately, set the stage for the design of Zn(II)-
dependent hydrolytic enzymes, the topic on which this dissertation is primarily focused. 
 
a) De novo design of a functional diiron protein 
 
DeGrado and coworkers have developed the Due Ferri (two-iron; DF) family of 
artificial metalloproteins as models for diiron and dimanganese enzymes, a diverse set of 
enzymes capable of catalyzing both hydrolytic and oxygen-dependent reactions.83,84 The 
binuclear metal site in these proteins is bridged by a combination of oxo, hydroxo, or 
carboxylate donors and although the protein folds of this diverse family of 
metalloproteins are complex, a simple four-helix bundle houses the active sites.15 
DeGrado et al. have designed four-helix bundle proteins to aid in understanding how 
polarity, solvent accessibility, and electrostatic environment influence the properties of 
these proteins, with a focus on diiron sites. The work demonstrates that minimal protein 
models can be used to track structural changes as small as a methyl group and connect 
them to the enzyme’s activity. Their success lies in iterative design and rigorous 
characterization of each model. Retrostructural analysis of diiron proteins was used to 
design the parent model, DF1, which is an antiparallel dimer of 48-residue helix-loop-
helix (α-2) motifs that binds a di-metal cofactor near its center.15 The helical bundle has a 
slight left-handed tilt as in classical four-helix bundles and antiparallel 4SCCs and its 
geometries may be discussed in terms of the heptad nomenclature described in Section 1c 
(Figure 1-12). Each helix has a single Glu residue in an a position which projects towards 
the center of the bundle. Two carboxylates bridge both metals, while the other two each 
interact with a single metal in a mono- or bidentate binding configuration. Two His 
residues are located at d positions, three residues away from the bridging Glu side chains 
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and coordinate each metal in a monodentate fashion to form an EXXH binding motif. 
Small side chains occur at the analogous d positions opposite the His residues and control 
oxygen and substrate access. Residues in the e and b positions line the two sides of the 
active site (e/b interface) and the other two sides are lined by c and g residues (c/g 
interface). Those residues along the b/e interface play primarily a structural role and are 
tightly packed. Those residues at the c/g interface form hydrogen bonds to the ligand His 
residues on one side and on the other side define entry to the active site. The a and d 
positions above and below the ligand residues form the top and bottom of the active site. 
These are often hydrophobic and their association provides part of the driving force for 
association of the α-helical bundle. 
DF1 was designed beginning with a D2-symmetric four-helix bundle of 
unconnected 21-residue helices and is made up of a Glu4His2 active site, where two Glu 
residues bridge the metals, the other two Glu residues are non-bridging ligands, and the 
Nδ of each His is bound to a metal (sequence 
DYLRELLKLELQLIKQYREALEYVKLPVLAKILEDEEKHIEWLETILG).15 
Additionally, second shell residues were added, which serve as geometric constraints and 
may be important to function. Asp35 forms a hydrogen bond with an active site His 
residue in a neighboring helix and Tyr7 (in a d position) forms a hydrogen bond with a 
 
 
Figure 1-12. Helix-wheel representation of the antiparallel four-stranded coiled 
coil structure surrounding the active site of a diiron protein. Residue positions 
are labeled according to the heptad repeat generally applied to coiled coils. 
Figure reproduced from ref. 15. 
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non-bridging Glu residue from a neighboring helix. A combination of hydrophobic and 
polar residues were chosen for the interfaces, helix-stabilizing polar residues were placed 
in the most solvent-accessible locations, and an interhelical loop was engineered in 
between each pair of helices. Structural analysis of di-Zn(II)-DF115, di-Mn(II)-DF1135, 
and apo-DF1136 revealed that the metal-binding site and surrounding secondary 
interactions are very similar to the intended design and largely preorganized for metal 
binding (Figure 1-13). Each iron is five-coordinate with a sixth vacant site lying on 
adjoining faces of the two metal ions, providing a potential binding site for exogenous 
ligands. Because the design of DF1 required the burial of six polar ionizable groups in the 
core of a four-helix bundle, the interior was packed with a large number of hydrophobic 
side chains to drive folding. These requirements for conformational stability are contrary 
to those for binding and enzymatic functions, as revealed by the difficulties in binding the 
metal cofactor (DF1 must be unfolded and refolded in the presence of metal to support 
binding) and the lack of any activity. In particular, analysis of the structure revealed that 
bulky Leu residues in d positions opposite the His-binding residues were likely blocking 
access of O2, which would limit its capability of supporting any activity. DF1 was 
redesigned to carve out a larger access site by mutating each of the Leu residues to either 
Ala or Gly (L13A-DF1 and L13G-DF1)135–138. These three designs were used to examine 
the thermodynamic costs of carving an active site access channel, with DF1 being the 
most stable and the Gly derivative being the least (a total loss of ~10 kcal mol-1). To 
confirm the presence of this designed cavity, the crystal structures of di-Mn(II)-L13A-
DF1 and di-Mn(II)-L13G-DF1 were solved.136 The X-ray structure of di-Mn(II)-L13A-
DF1 revealed three dimers in the ASU, all nearly identical to those observed for the di-
Zn(II)- and di-Mn(II)-DF1 structures.138 Further, an aqueous channel is formed by the 
Leu to Ala substitutions and is filled by ordered water molecules and evidence of a metal-
bridging dimethyl sulfoxide (DMSO) molecule. The X-ray crystal structure of di-Mn(II)-
L13G-DF1 shows that with substitution by the smallest amino acid, Gly, the size of the 
aqueous channel increases even more.137 There are now four independent dimers in the 
ASU, more water molecules present around the dimetal cofactor and no evidence of 
bound DMSO.  More interesting is the presence of two different coordination 
environments around the di-Mn(II) centers (Figure 1-14). Three of the 
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crystallographically independent dimers in the ASU have bridging water molecules and 
an intermetal distance of 3.6 Å. However, the fourth has two terminal water molecules, 
one coordinated to each metal and trans to the liganding His residues. The intermetal 
distance in this dimer is 4.2 Å. Superimposition of the C-terminal helices (those 
containing the HXXE liganding site) reveal no difference in the four dimers but the N-
terminal helices (those containing only a single liganding Glu residue) occupy different 
positions in the dimer containing the distinct metal coordination site. Particularly, two 
 
 
Figure 1-13. Ribbon diagrams of the structures of metal-bound and apo-DF1. (a) 
The X-ray crystal structure of di-Zn(II)-DF1 (pdb 1EC5)15. (b) The X-ray crystal 
structure of di-Mn(II)-DF1 (pdb 1OVR)135. (c) The NMR structure of apo-DF1 
(pdb 1NVO)136. The helix-loop-helix motif in front of the ligands is shown as 
transparent to give an improved view. 
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copies of the N-terminal helices shift in opposite directions; this sliding helix-induced 
shift is what leads to the increase in the metal-metal bond length. It is postulated that this 
may occur in native enzymes to accommodate coordination environment changes; 
however, it would likely be difficult to observe in a complex, large molecule. Structural 
analysis of DF1 and its mutants with bound di-Zn(II) and di-Mn(II) demonstrate that the 
overall protein fold and general coordination environment around the dimetal site are 
retained with introduction of a metal site access channel. Although the DF1 constructs 
have proven useful for detailed structural characterization (as their stability facilitates 
crystal growth), they have only limited solubility and therefore cannot be fully 
characterized in solution. To improve the properties of DF1, some hydrophobic residues 
on the surface of L13A-DF1 were replaced with polar residues and a redesigned 
 
 
Figure 1-14. 2Fo-Fc electron density maps of the dinuclear metal-binding site of 
di-Mn(II)-L13G-DF1 in the dimer (one of four in the ASU) with terminal waters 
bound to each metal (top) and in one of the dimers with a bridging water 
(bottom). Figure reproduced from ref. 83.  
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interhelical loop in DF2 and then a longer interhelical loop was incorporated in DF2t.139–
143  
Next, in searching for functionality, DFtet was designed by bridging rational 
design with a combinatorial approach to facilitate preparation of a variety of mutants.144 
The results obtained from the DF1 and DF2 models indicated three main aspects to be 
considered in order to obtain stable and functional models: interhelical turn design, 
residues responsible for primary and secondary ligands, and residues that define the 
active site access channel. In order to fully examine how systematic changes would affect 
these aspects, a large number of combinations of mutations would be required. DFtet was 
designed with four disconnected helices that could be separately prepared then 
combinatorially assembled. To this end, A2B2144 and AA’B2145 heterotetrameric 
complexes were assembled and renamed DFtet. Design of these sequences implemented 
the use of negative protein design by destabilizing both homooligomeric folds and 
undesired heterotetrameric topologies. DFtet-A and DFtet-B only fold and assemble with 
the desired stoichiometry when mixed in a 1:1 ratio. A substrate pocket was designed into 
 
 
Figure 1-15. Comparison of DF1 and DF3 structures. (a) Crystal structure of di-
Zn(II)-DF1 (pdb 1EC5). (b) Surface representation of the crystal structure of di-
Zn(II)-DF1 to display the accessibility to the dimetal site. (c) NMR structure of 
di-Zn(II)-DF3 (pdb 2KIK). (d) Surface representation of the NMR structure of 
di-Zn(II)-DF3 to show the increased accessibility to the active site over DF1. The 
different residues in position 9 (lime) and 13 (cyan) are highlighted. Metal ions 
are colored magenta. Figure reproduced from ref. 82. 
!
 30 
the interior of this symmetrical DFtet that lead to the development of an O2-dependent 
phenol oxidase.6 Specifically, G4-DFtet, which had Gly residues substituted for Leu15 
and Ala19 in both A chains and, as a result, the least steric restrictions of all the variants, 
showed rapid formation of the oxo-species with no detectable intermediates. G4-DFtet 
could perform the two-electron oxidation of 4-aminophenol (4AP) to benzoquinone 
monoamine with a 1000-fold rate enhancement over the background reaction and at least 
100 turnovers. O2 oxidizes the diferrous form of the protein, giving rise to the diferric 
form which reacts with 4AP. The resulting diferrous form is oxidized again to complete 
the catalytic cycle. The rate was decreased 2.5- and 5-fold when either Gly residue at 
position 19 or 15 was changed to Ala. The catalytic efficiency is therefore sensitive to 
changes the size of a methyl group, and demonstrates the correlation between catalytic 
activity and size of the active site cavity. 
Despite this success with DFtet, its borderline stability, complex stoichiometry, 
and tendency to undergo ligand-exchange reactions limited full characterization. 
Unfortunately, DF1 is not stable enough to handle the analogous Leu15 and Ala19 
mutations in DFtet (Leu9 and Leu13 to Gly) to accommodate the phenol substrate. The 
interhelical turn sequence was therefore modified to create more stabilizing electrostatic 
interactions leading to DF3.82 The solution structure of di-Zn(II)-DF3 demonstrates that 
the structure remains nearly identical to the design, with the exception of a larger access 
channel (Figure 1-15). This site could also bind iron, undergo reversible oxidation-
reduction cycles, and catalyze the oxidation of 4AP for at least 50 turnovers. The protein 
follows Michaelis-Menten kinetics in the presence of O2, with an efficiency of 23 M-1 s-1, 
KM = 1.97 ± 0.27 mM and kcat = 0.045 s-1 (Table 1-3). The designed metalloprotein could 
Table 1-3. Comparisons of the kinetics of 4-aminophenol by designed 
diiron proteins. 
Catalyst kcat (s-1) KM (mM) kcat/KM (M-1 s-1) 
di-Fe(III)-DF3a 0.045 ± 0.003 1.97 ± 0.27 23.0 
G4DFtetb 0.022 ± 0.002 0.83 ± 0.06 25.7 
a. Taken from reference 82; measured at pH 7.0 and 25° C. The protein can 
perform 50 turnovers over the course of one hour.  
b. Taken from reference 6; pH 7.0 and 25° C. The protein performed > 100 
turnovers. ~1,000-fold rate enhancement observed over the background 
reaction (from comparing initial rate in presence and absence of protein). 
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also catalyze the oxidation of other related substrates, such as 3,5-di-tert-butylcatechol 
(3,5-DTBC) (with a five-fold higher kcat than that for 4AP) and p-phenylene diamine 
(expected to bind more weakly, and had a 75-fold lower kcat/KM than that for 4AP). No 
activity was observed for o-phenylenediamine. These results are all consistent with the 
anticipated catalytic properties of di-Fe(III)-DF3. Analysis of the crystal structure of di-
Zn(II)-DF3 revealed that the L9G and L13G mutations created an active site cleft which, 
at its narrowest, was the width of a phenyl ring. Substitutions at the 3 and 5 positions 
could be accommodated in wider regions of the cavity. Thermodynamic analysis of a 
series of DF1 mutants versus DF3 revealed that the required functional mutations were 
relatively destabilizing, although the redesigned turn sequence helped to compensate for 
this. These requirements for activity, which lead to dramatic destabilization of the protein 
structure, demonstrate the tradeoff between conformational stability and catalytic 
function, something that is particularly apparent in metalloproteins because of the 
additional requirement for balance between often opposing metal-binding and functional 
requirements.  
 
Figure 1-16. Ribbon diagram showing the structure of the 3His-G2DFsc variant 
(pdb 2LFD) with the added metal-binding His residue (H100) and supporting 
mutations (I37N, L81H). Although kinetic data is reported for the 3His-G4DFsc 
variant, the structure shown here contains only two Gly mutations because of 
increased stability during data collection (this variant also showed N-oxygenase 
activity, albeit slower than the G4-variant). Figure reproduced from ref. 81. 
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The success of these designs suggested it might be feasible not only to transfer an 
active site from a native enzyme onto a minimal de novo designed model, but also to alter 
its reactivity through a redesign approach. The target diiron enzyme for this 
reprogramming is AurF (a p-aminobenzoate N-oxygenase), which performs the N-
oxygenation of anilines, and is the only structurally characterized N-oxygenase with a 
diiron center. In order to reproduce the structure of this enzyme, a third His residue 
needed to be incorporated into the active site. Since this would be an asymmetric 
substitution (single mutation), the single chain monomeric DFsc protein was used 
(designed by specifying 26 residues and allowing the remaining 88 to be modeled 
computationally).146 The NMR structure of di-Zn(II)-DFsc confirms that the fold of the 
protein is retained.147 Analysis of DFsc in the context of ferroxidase activity revealed that 
while it demonstrated rapid formation of a diferric site in the presence of oxygen, it was 
not an oxygen intermediate, as with the dimeric and tetrameric DF proteins but an off-
pathway iron-tyrosinate complex.148,149 Expanding the substrate access channel by 
preparing a quadruple Ala-Gly mutant (G4-DFsc; positions analogous to those described 
for DF3 and DFtet) lead to a minimization of formation of this complex and rapid 
oxidation to form a µ-oxo-bridged diferric cluster.81 G4DFsc also catalyzes 4AP 
oxidation, like other members of the DF family with open active site access channels, and 
with a rate on the same order of magnitude as DFsc. Subsequently, His was substituted 
for Ile in position 100, structurally in the same position as in AurF. To alleviate the 
resulting steric clashes and balance out surrounding electrostatic interactions, three more 
substitutions were made adjacent to the His residue to form a polar network (Figure 1-
 
Figure 1-17. Proposed reaction scheme for N-hydroxylation of p-anisidine. Figure 
reproduced from ref. 81. 
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16). Fortunately, 3His-G4DFsc is well folded in the presence of divalent metal ions but, 
unlike G4DFsc, does not fold in their absence, as might be expected for incorporating a 
number of helix-destabilizing substitutions in addition to introduction of three polar 
substitutions within the hydrophobic, solvent-inaccessible core. Regardless, this new 
construct has 4AP activity reduced to near-background levels, but can now catalyze the 
N-hydroxylation of arylamines such as p-anisidine (no N-hydroxylation reactivity is 
observed for G4DFsc) and other related substrates (Figure 1-17). This shift in reactivity is 
dramatic, especially considering that just four residues were mutated, and only one 
directly to the metal-binding site. Although difficult to discern in complex native diiron 
proteins, this study on relatively small de novo models suggests that it is the single His 
residue that directly contributes to the reactivity change. More broadly, this study is an 
elegant demonstration of how active site structure can be directly correlated with 
function, in the absence of the bulk of the surrounding protein matrix found in native 
metalloproteins.  The loss in stability of the apo-construct is unfortunate; however, the 
presence of divalent metals enables characterization and reactivity studies. This decrease 
in stability with the introduction of function is another demonstration of the tradeoff 
between function and stability. The fact that metal ions stabilize the fold illustrates this 
interplay and how de novo design can be used to better understand the relationships 
between metal binding, protein folding, and function. 
 
b) Dirhodium peptide catalysts for structure-selective side-chain modification 
 
In the past few years, the Ball group has focused on the preparation of dirhodium-
induced α-helices that form heterodimeric 2SCCs for a number of applications of interest 
to enzymatic function.150 Particularly attractive about their strategy is that they have 
incorporated organometallic fragments in order to prepare bioinspired catalysts not 
remotely similar to what is found in nature. This group showed that they could prepare 
peptide complexes with dirhodium that would be stabilized or induced to form α-helices 
upon binding to two carboxylate groups separated by four residues and in some cases, 
three.69,109 Although other peptides have been examined (and sequences as short as 9 
residues could be stabilized by dirhodium binding to an i, i + 4 carboxylate motif), much 
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of the work has focused on the E3/K3 heterodimeric 2SCC originally reported by 
Hodges.151 The E3/K3 coil has complementary charges at the positions flanking the 
helical interfaces, e and g, to direct heterodimerization. By incorporating a dirhodium 
complex into the K3 coil at an i, i + 7 Glu motif, coiled coil formation could be inhibited, 
demonstrating the importance of the spacing of the Glu residues.  K3a,eRh2, in which Glu 
residues are present at i, i + 4 positions can be prepared and forms a heterodimeric coiled 
coil with the E3 coil. By incorporating a reactive Trp residue at the complementary g 
position of E3 (E3gW) and combining this substrate with the dirhodium metallopeptide 
(catalyst) and a diazo reagent, a 103 rate enhancement for Trp modification over free 
Rh2(OAc)4 reagent was observed (Figure 1-18).152,153 Further controls demonstrate that 
this is a site-selective molecular recognition event. Specifically, modification only occurs 
when the target Trp residue is placed in a complementary position of the coiled coil. 
When Trp is placed in a random position of the complementary strand, reactivity shows 
no improvement over the control reaction with free Rh2(OAc)4. Further, attempts to 
 
 
Figure 1-18. Representation of structure-selective peptide modification by a 
rhodium-bound peptide catalyst. 1 is the diazo reagent. X is the amino acid to be 
modified (Trp is discussed in the text). Figure reproduced from ref. 154. 
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modify E3eW or K3gW with K3a,eRH2 were not successful. This work has since been 
extended to include site-specific modification of a number of other amino acids (even in 
the presence of the more reactive Trp), some of which do not have any previous methods 
reported for their modification, demonstrating that molecular recognition through coiled 
coil formation can override the inherent chemical reactivity of the substrate.153,154 
Further, this work has been extended to demonstrate modification of larger natural targets 
in complex systems.155,156 The Ball group has also shown that reactivity can be 
specifically inhibited through binding a His-containing substrate peptide to the 
metallopeptide catalyst.157 Both of these mechanisms are important to the development of 
catalysts with enzyme-like characteristics including selectivity and sequence-specific 
inhibition. Overall, this work demonstrates the utility of designed peptide systems for 
performing organometallic chemistry in aqueous solutions. Related work on 
incorporating organometallic complexes into native proteins for this type of chemistry 
has also been reported26–28, but this is the only example which exploits the known 
interactions in a de novo coiled coil system for site-specific organometallic chemistry. 
 
4. Towards designing hydrolytic zinc metalloenzymes 
 
The focus of my doctoral work, on designing hydrolytic zinc metalloenzymes, 
warrants a more thorough discussion of zinc proteins in general. Zinc is an essential 
cofactor in thousands of proteins. As one of the most prevalent transition metal cofactors 
in biological systems, it plays structural, signaling, and regulatory roles, and is found in 
all six classes of enzymes (most commonly hydrolases).158 Discovery of its presence as 
the active metal in the hydrolytic metalloenzyme carbonic anhydrase (CA) in 1939159 was 
followed by its characterization in carboxypeptidase in 1950,160 and soon after, in 
enzymes of all classes.161 In 1990, Vallee and Auld published a report analyzing the 
coordination spheres around Zn(II) in the available protein crystal structures, including 
examples from most of the enzyme classes.162 Here, the authors introduced the spacer 
rule for native zinc proteins, in which at least two of the liganding residues exist within a 
few residues (1-3) of each other in the primary sequence, and the third was separated by a 
longer spacer much more varied in length (5-200 residues). This rule, in which the shorter 
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spacer is proposed as a nucleus for the Zn(II) site while the longer spacer allows for some 
flexibility, remains rarely violated. The general guidelines for the coordination of Zn(II) 
in proteins have been described in a number of reports.163 More than 99% of the time 
Zn(II) is coordinated by a combination of His, Glu/Asp, and Cys residues. Since Zn(II) is 
a borderline metal according to the hard-soft acid base theory, it can bind well to both 
hard (nitrogen, oxygen) and soft (sulfur) ligands. Specifically, Zn(II) can be coordinated 
by the Nδ or Nε  atom of the His ring, the Oε1 or Oε2 atom of Glu/Asp (syn or anti), or by 
the S of Cys in either an end-on or bridging fashion (Figure 1-19). More rarely, Zn(II) 
will also bind to the phenolate group of Tyr164, the carboxamide oxygen of Asn or 
Gln165,166, or to a protein backbone carbonyl oxygen.167 There are several reasons for the 
prevalence of Zn(II) as a catalyst in enzymes. Compared to other first-row transition 
 
 
Figure 1-19. Zinc(II)-amino acid side chain binding modes as described in the 
text. Most zinc ligands in proteins are the side chains of cysteine (S-donor), 
histidine (N-donor), and glutamate or aspartate (O-donors). 
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metals, Zn(II) stands out because its filled d orbital precludes it from participating in 
redox reactions and allows it to function solely as a Lewis acid. This particular property 
makes Zn(II) an ideal metal ion for reactions requiring a redox-stable cofactor to function 
as a Lewis acid catalyst. As a d10 metal ion, Zn(II) has zero ligand field stabilization 
energy, so no geometry is inherently more stable than another. This lack of an energetic 
barrier for Zn(II) may be important for its catalytic properties, allowing for changes in 
coordination number throughout a catalytic cycle (from four- to five-coordinate, for 
example, to accommodate the intermediate) and for alterations in the reactivity of the 
metal ion. Additionally, Zn(II) complexes can undergo rapid ligand exchange, enhancing 
the ability of Zn(II) to effect a catalytic cycle through efficient product release. Although 
no coordination number or geometry is inherently more stable, most zinc-dependent 
proteins feature a resting state with a tetrahedrally coordinated zinc center (in some cases, 
Zn(II) is found in a five-coordinate trigonal bipyramidal geometry). This is in contrast to 
simple zinc complexes which usually have higher coordination numbers and are often 
octahedral in solution.168 Clearly, the protein plays a role in enforcing a lower 
coordination number. Zinc sites in proteins have been classified into three general 
categories: structural, catalytic, and co-catalytic.162,169 Structural sites have a saturated 
coordination sphere with all metal ligands originating from amino acids and confer 
stabilization on the tertiary structure. On the other hand, catalytic sites require an open 
coordination sphere with at least one water molecule and three or four protein ligands, 
and participate directly in the bond-making/bond-breaking process of a chemical 
reaction. Co-catalytic sites have several metals in close proximity, where one is directly 
catalytic and the others serve to enhance the activity. It is worthwhile to note that while 
these basic guidelines for Zn(II) coordination are generally true, additional principles 
continue to emerge for Zn(II) sites at protein interfaces, inhibitor, and transient binding 
sites in Zn(II)-transporting and Zn(II)-sensing sites.104,170 
Although Zn(II) is required for the function of enzymes in all six enzyme classes, 
most zinc enzymes are hydrolases (aminopeptidases, carboxypeptidases, matrix 
metalloproteinases, phosphatases, β-lactamase, etc.). CA catalyzes the nucleophilic 
addition of OH- and officially belongs to the lyase class of enzymes, but will be discussed 
here in the context of hydrolytic enzymes (notably, while CO2 hydration is the 
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physiological reaction for CA, this enzyme can also catalyze the hydrolysis of a number 
of other substrates including the often used and well-studied p-nitrophenyl acetate, 
pNPA.171,172). The zinc hydrolase superfamily shares a common structural scaffold 
consisting of an eight-stranded β-sheet flanked by six α-helices. While the active site is 
located at the end of the central four β-strands, no overall conservation between the active 
sites exists.173 Some members of this superfamily are monozinc enzymes 
(carboxypeptidase, thermolysin) while others contain co-catalytic zinc sites 
(aminopeptidase, β-lactamase, alkaline phosphatase). While the liganding residues 
around the catalytic Zn(II) ions follow the spacer rule, their identities are not 
conserved.163 The active sites can be comprised of differing residues (most commonly 
His2Glu/Asp(H2O) and His3(H2O) but sometimes also CysHis2(H2O), Cys2His(H2O), and 
even Cys3(H2O)) where the residues can be located on a combination of loops, β-sheets, 
and α-helices. One common feature is that the active sites are generally buried within the 
protein structure. There are multiple evolutionarily unrelated families for CA (α-, β-, γ-, 
δ-, and ζ-CAs)174,175, although all are zinc enzymes. All 16 known isoforms of the most 
extensively studied α-family of CAs share a conserved monomeric tertiary structure 
mainly comprised of β-strands.176 Specifically, the structure is made up of 10 β-strands 
which form a large, twisted β-structure surrounded by six α-helices on the surface of the 
molecule. The active site is located at the bottom of a cavity that reaches almost to the 
center of the molecule where Zn(II) is bound to three His residues and a solvent molecule 
in a tetrahedral geometry. The His residues are located along adjacent β-strands, two with 
a one-residue spacer between them on a single strand (His94 and His96) and the third, 
separated by a longer spacer, at position 119. These examples of zinc enzymes from the 
hydrolase and related lyase classes clearly illustrate variability in the coordination 
environment, yet most hydrolases are contained within a similar overall structure 
centered mainly around β-sheets where, often, at least one ligand originates from a loop 
region or the end of a secondary structural element. Numerous differences in the protein 
structures encompassing hydrolytic zinc centers (some are small and monomeric whereas 
others are present as more complicated, multimeric structures) may tune their interactions 
with substrates. Determining the patterns, if they exist, between the protein folds and 
function of each zinc site is complicated at present, although important questions are 
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what the role of the protein fold is on the metal center’s activity and whether it is 
necessary or simply a remnant of evolution. 
Along similar lines, while the variability that can be achieved through just four 
basic amino acids and their assorted binding modes is striking, it has been demonstrated 
that it is not simply the first coordination sphere that differentiates one Zn(II) site and 
function from another. Although the importance of secondary interactions is well 
known170,177, reliable guidelines such as those for the first coordination sphere around 
Zn(II) have yet to be well defined. For example, not only is a ZnN3 site present in the 
metalloenzyme CA178 and many matrix metalloproteinases163, both where activation of a 
Zn(II)-bound water molecule to a hydroxide nucleophile occurs, it also exists as a 
 
 
Figure 1-20. ZnHis3 sites in various proteins.104,170 a) Insulin (pdb 1AIO), in 
which Zn(II) organizes the hexamer with His ligands originating from three 
different monomers.179 b) Carbonic anhydrase II (pdb 2CBA), in which Zn(II) 
forms a hydrolytic active site and each of the three His ligands are on β-sheets.178 
c) Matrix metalloproteinase adamalysin II (pdb 1AIG), in which Zn(II) forms a 
hydrolytic active site with two His ligands on an α-helix and the third from a 
loop.268 d) Serine protease tonin (pdb 1TON), in which Zn(II) binding inhibits 
activity.180 e) Zinc transporter ZnuA (pdb 1PQ4), in which the structure mediates 
Zn(II) mobility for transport.181 
!
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structural anchor in insulin179 (each His ligand originating from a different subunit), as an 
inhibitor in serine protease tonin180, and, in ZnuA181, the ZnN3 site transports Zn(II) in the 
periplasm (Figure 1-20). This variability generates a number of questions: how can a 
single first coordination sphere be modified by the protein environment to result in such a 
wide variety of metalloprotein functions? What are the ligands and structures necessary 
for a given function? Is the native protein fold critical for optimal function? Are there 
minimal changes that can be made around the metal site to alter or completely change the 
function? How many different functions can a single metal site perform? While direct 
biochemical studies on existing metalloproteins have begun to answer some of these 
questions, it is difficult to imagine a situation where a native enzyme can be mutated to 
determine the baseline requirements of the first coordination sphere in the absence of 
most of the surrounding protein matrix (the metal site would likely fall apart completely). 
Of course, this can be (and is often) approached by synthesizing small molecule models 
of the active sites of zinc metalloproteins, but this approach comes with a number of 
limitations including difficulties in working under aqueous conditions, in using the 
natural amino acid ligands, in stabilizing lower coordination numbers within a 
hydrophobic core and in assessing the influence of hydrogen bonding and electrostatics 
on catalytic activity.182 Protein design is an effective yet challenging approach to 
recreating functional metal sites found in native enzymes. With this process, one may 
replicate a protein-like environment more straightforwardly than with synthetic models 
(using the real amino acid ligands, aqueous environment, etc.). As described earlier 
(Section 1a, b), the design itself can be approached in different ways (redesign or de novo 
design).3–11,183,184 
 
a) Zn(II) as an attractive catalyst in proteins 
 
Zn(II) ions serve as powerful catalysts in many hydrolase enzymes with diverse, 
though generally related, mechanisms.182,185,186 The reactivity of Zn(II) in enzymes 
centers around a Zn-OH2 moiety (Figure 1-21). In the most common basic mechanism, 
the Lewis acidic Zn(II) center simply promotes deprotonation of the coordinated water to 
generate a hydroxide species at neutral pH (as in the mechanism for CA187–189). For less 
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Lewis acidic Zn(II) centers (such as that in carboxypeptidase which has an anionic Glu 
residue in the coordination sphere190), further activation may occur by interaction with an 
adjacent base (such as a Glu residue) to generate the hydroxide species. A third type of 
basic mechanism involves displacement of the water molecule by substrate, which can 
then be activated (such as in 5-aminolevulinate dehydratase191 or liver alcohol 
dehydrogenase192). There are also examples in which zinc can activate thiols towards 
nucleophilic attack, such as in the Ada DNA repair protein mechanism.193,194 As will 
become apparent throughout the rest of this chapter, designed hydrolytic zinc proteins are 
generally intended to operate by the simple deprotonation mechanism and have not yet 
encompassed the design of nearby basic residues to assist deprotonation (a feature of 




b) Designing zinc-binding proteins 
 
De novo sites in de novo and pre-existing scaffolds 
 
 
Figure 1-21. General mechanisms for Zn(II) enzymes. a) Ionization to form a 
Zn(II)-hydroxide nucleophile. b) Polarization with the assistance of a general 
base to generate a nucleophile. c) Displacement by substrate that can be 
subsequently activated to generate a nucleophile. 
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Given the importance of zinc, it is not surprising that zinc site design was among 
the initial metalloprotein design reports. In the earliest work, ZnHis3 sites (as inspired by 
CA) were engineered into the de novo designed four-helix bundle protein, α476, and the 
redesigned antibody-like protein, minibody90. In the case of α4, the binding of Zn(II) to 
the His3 site helped to decrease the protein’s molten-globule like properties (due to a lack 
of conformational specificity in the core) and induce a more native-like protein fold, 
although no structure or binding affinity was reported (Section 1c).49 In the minibody 
reported by Pessi et al., a 61-residue all β-sheet structure, the dissociation constant for 
Zn(II) binding was estimated to have a ~10-6 M lower limit (Figure 1-22a).90 While this 
represents fairly strong binding, it is relatively weak when compared to native zinc 
enzymes which generally have dissociation constants in the nM to pM range.195–198 A 
Zn(II)-binding His3 site was also introduced into the retinol binding protein in a solvent-
exposed position on the surface.199 The dissociation constant for Zn(II) binding to this 
site (36 ± 10 nM) is somewhat stronger and closer to the range for native zinc proteins. 
The geometry, based on competition with chelating ligands, is likely octahedral, with 
three open coordination sites.200 Soon after, a scorpion toxin, charybdotoxin (37 amino 
acids long and comprised of a short α-helix on one face and an antiparallel triple-stranded 
β-sheet on the opposite with three stabilizing disulfide bonds in the interior), was used as 
 
 
Figure 1-22. Designed ZnHis3 sites. a) Modeled structure for the design of the 
minibody and its predicted metal-binding site (His3). Reproduced from ref. 90. b) 
Model of the redesigned scorpion toxin charybdotoxin (orthogonal views) with a 
His3 metal-binding site. Disulfide bonds are shown in yellow. Metal-binding 
ligands are shown in red. Reproduced from ref. 201. 
!
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a small scaffold for the incorporation of a His3 site (Figure 1-22b).201 Nine mutations 
were made to incorporate the metal-binding site, including engineering in three His 
residues and including the Gln and Glu residues found in CA which form hydrogen bonds 
to two of the primary His ligands. While no X-ray crystal or NMR structures are 
reported, CD and 1H NMR indicates the structure is largely retained relative to the parent 
sequence. The dissociation constant for Zn(II) binding is 5.3 (±0.4) x 10-6 M and, 
although no catalytic activity was reported, the design demonstrates the achievement of a 
stable, yet solvent-exposed metal-binding site at the surface of a miniprotein.197,202 Table 
1-4 summarizes the known dissociation constants for many of the designed Zn(II)-
binding sites that are reported. 
The de novo designed four-helix bundle, α4, was also used as a scaffold for the 
incorporation of a closed-sphere ZnCys2His2 site (Zα4), much like the structural site 
found in zinc fingers (ZFs) (Figure 1-23a).80,203 Co(II) was used as a spectroscopic probe 
to demonstrate successful design of a tetrahedral site. Mutants of this design, in which 
one ligand was removed at a time (by substitution with Ala) in order to generate an open 
coordination site, were also tetrahedral, although the Co(II)-binding affinities were all 
decreased by at least one order of magnitude. Overall, the Cys residues were concluded to 
be stronger determinants for Co(II) binding than His, which is not unexpected since the 
negative charge on the Cys thiolate residue is known to provide a stronger binding 
contribution.204–207 Klemba et al. reported the redesign of the B1 domain of IgG-binding 
protein G (a 56-residue protein with a four-stranded β-sheet crossed by a single α-helix) 
to incorporate a closed-sphere His3Cys site for binding Zn(II) (Figure 1-23b).208 Co(II) 
substitution confirmed the presence of a tetrahedral site and, based on competition, Zn(II) 
binding was estimated to be on the order of 10-9 M. There are also numerous other studies 
involving the design of a variety of peptide ligands for the preparation of metal sites 
meant to mimic ZF proteins (coordination environment Zn(Cys)4-x(His)x where x = 0, 1, 
or 2), which are beyond the scope of this chapter.209,210 Overall, these examples of 
designed Zn(II) sites with four protein ligands generally display higher affinities than the 
designed sites with three protein ligands discussed above. It is worth noting that no strict 
correlation exists with the number of ligands bound in the first coordination sphere for 
native zinc enzymes.104,195,198 This is likely due to the incorporation of secondary 
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structure interactions and demonstrates the utility of protein design to uncover features of 
metal binding that would otherwise be difficult to determine in a native system. 
 
Metal-mediated stabilization of protein structures 
There are a number of examples where designed Zn(II)-binding sites have 
resulted in enhanced folding of partially or completely unfolded peptide 
structures.88,91,110,117,207,211–214 As described in Section 2a, a His3 site was introduced into a 
Table 1-4. A comparison of Zn(II)-binding affinities to selected designed proteins. 
Design Coordination Site Kd (Zn(II)) (M) pH ref 
Minibody His3 ~10-6 na a 
Retinol binding protein His3 36 (±10) x 10-9 na b 
Charybdotoxin His3 5.4 (±0.4) x 10-6 6.5 c 
IZ-3aH His3 9 x 10-6 7.0 d 
IZ-3adH His6 23 (±2) x 10-6 7.0 e 
Zα4 His2Cys2 2.5 x 10-8 7.5 f 
Zβ1M,A,L His3Cys ~10-9 7.5 g 
Trx[ZS].C, F His2Cys2 ~10 x 10-9 7.5 h 
Trx[ZS].A, B, E His2Cys2 ~1 x 10-6 7.5 h 
BABZ5 His2Cys2 2.2 x 10-6 7.3 i 
IGA Cys4 
0.4 x 10-15 pH 8.0 j 
4 x 10-12 pH 7.0 j 
GGG 
Cys4 
18 x 10-18 pH-independent k 
0.5 x 10-12 pH 7.4 k 
HisCys3 
0.7 x 10-15 pH-independent k 
0.5 x 10-12 pH 7.4 k 
His2Cys2 
40 x 10-15 pH-independent k 
0.5 x 10-12 pH 7.4 k 
αββ Zn(II)-hydrolase His3 800 x 10-6 na l 
a. Taken from reference 90. 
b. Taken from reference 199. 
c. Taken from reference 201. 
d. Taken from reference 117. 
e. Taken from reference 110. 
f. Taken from reference 80. 
g. Taken from reference 208. 
h. Taken from reference 212. 
i. Taken from reference 91. 
j. Taken from reference 214. 
k. Taken from reference 207. 
l. Taken from reference 250. 
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de novo designed 3SCC, IZ (YGG(IEKKIEA)4) to generate IZ-3aH which folds in the 
presence of Zn(II) (Kd = 9 µM), although no X-ray crystal structure was obtained.117 The 
same group reported a similar 3SCC, but with six His residues available for binding in an 
octahedral geometry with a Kd for Zn(II) binding of 23 ± 2 µM.110 These affinities remain 
in the same range as those described above with three protein ligands (Table 1-4). 
Wisz et al. reported the semi-automated design of a series of ZnCys2His2 centers 
into the non-metalloprotein thioredoxin (Trx, using the program Dezymer215) (Figure 1-
24a).212 Dezymer was used to identify sites where appropriate amino acids could be 
engineered to create a metal-binding site with predetermined geometry, in this case 
tetrahedral. Visual inspection identified seven variants with buried potential metal sites 
and few steric clashes with the backbone. Five of seven experimentally characterized 
mutants bound Co(II) in a tetrahedral geometry with strong dissociation constants for 
some (2-4 µM) and weak for others (150-250 µM). Zn(II) binding (measured by 
displacement) was 2-3 orders of magnitude stronger than Co(II) (nM to µM). The 
strongest Kd’s were for structures in which the apo form was stable and metal binding 
 
 
Figure 1-23. Designed ZnHisxCysx sites. a) Model of Zα4. The side chains 
(clockwise from top right) are Cys21, His25, Cys47, and His51. Reproduced from 
ref. 203. b) Model of the metal-binding site in the B1 domain of Streptococcal 
protein G. The ribbon diagram represents the designed Zβ1M. The side chains 
around the metal-binding site are His16, His18, His30, and Cys33. Reproduced 
from ref. 208. 
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further increased the stability (Trx[ZS].C, F). In two cases (Trx[ZS].A, B), the apo form 
was unstable and metal binding induced folding (Co(II) Kd’s ~150 µM). In the fifth case 
(Trx[ZS].E), the apo form was stable but metal binding decreased the stability. The weak 
metal-binding affinity for this variant results from clashing steric interactions within the 
metal coordination sphere. Thermodynamic analysis revealed that all variants bound 
metal to the unfolded state and the observed metal-mediated stability is a consequence of 
differential binding to the folded native state and unfolded structures, although the 
dominant factor for binding to the unfolded state is unclear. This work demonstrates how 
the design of a family of similar sites within the same scaffold can lead to an 
understanding of how both the intrinsic properties of the metal center and the surrounding 
protein matrix can affect the metal-binding affinity (and stabilization). In this case, the 
metal dictates geometry and the thermodynamic price paid by the protein to 
accommodate the metal is reflected in the binding constant. Important considerations for 
designing metal-binding sites are that packing interactions in the binding site should be 
carefully considered to avoid costly reorganization energies and binding to the unfolded 
state should be destabilized (negative design). 
Another example which examined the design of a ZnHis2Cys2 site in several 
locations of a protein (de novo designed DS119 with βαβ structure) was reported by Zhu 
 
 
Figure 1-24. Designed ZnHis2Cys2 sites. a) The distribution of the designed 
Cys2His2 sites in thioredoxin (letters identify each design). Reproduced from ref. 
212. b) Structure model of BABZ5 protein. Zn(II) is indicated as a sphere and 
coordinating residues (two His and two Cys) are shown as sticks. Reproduced 
from ref. 91. 
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et al (Figure 1-24b).91 It was found that the Zn(II) sites designed in the core generally 
destroyed the folding even in the presence of zinc, while those at flexible terminals or 
loops displayed Zn(II)-induced aggregation, with Kd’s in the 2-20 µM range, however, 
the binding stoichiometry was 1:1 in only one case (BABZ5, Kd = 2.2 µM). These 
observations result from a balance between the energy provided by metal binding and the 
cost of folding the protein structure. In the cases where the engineered ligands destroy the 
core-packing of the protein, energetic contributions from the binding of Zn(II) are not 
enough to recover the fold. 
Overall, these design studies where metal binding induces or further stabilizes a 
protein fold demonstrate a connection between the binding constant and the energy 
required to fold a given protein. The formation of metal-ligand bonds provides a 
favorable enthalpic contribution to the free energy of protein folding. There are also 
entropic contributions from the release of water molecules from the binding site and the 
solvated metal upon binding. In an effort to separate protein-protein and metal-protein 
contributions towards the free energy of folding, Reddi et al. reported the thermodynamic 
analysis of Zn(II) binding to a Cys4 site in a minimal, unstructured, 16-mer peptide, 
GGG (a variant of IGA with the sequence NH2-KLCEGG.CGGCGGC.GGW-
CONH2).213 Petros et al. had initially reported the design of a structural ZnS4 binding site 
in a de novo designed 16-amino acid peptide ligand, IGA (sequence H2N-KLCEGG-
CIGCGAC-GGW-CONH2)214 and found apparent dissociation constants for Zn(II) at pH 
8.0 of 0.4 fM and at pH 7.0 of 4 pM (similar to that for a redesigned ZF, CP1-CCCC, 1.1 
pM216). These are well within the range observed for natural zinc proteins like 
metallothionein (0.1 pM at pH 7.0)198, yet (at pH 7.0) weaker than those of the zinc 
sensor proteins ZntR and Zur (1.5 fM and 1.1 fM, respectively).195,217 It was suggested 
from this work that the formation of the ZnCys4 site provides -22.1 kcal mol-1 driving 
force for protein folding. The goal of the work using GGG (designed to more closely 
resemble structural Zn(II) sites than IGA, which was originally based on a [4Fe-4S] 
binding motif) was to decouple the metal binding and protein folding events by choosing 
a structure in which the free energies of the folded and unfolded states are identical. The 
pH-independent dissociation constant for Zn(II) binding to GGG is 18 aM, indicating 
that a ZnCys4 site can provide up to -22.8 kcal mol-1 driving force for protein structure 
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stabilization (Figure 1-25).207 Further, the majority of the driving force is due to 
dehydration of the metal and binding site so the process is largely entropy-driven. Zn(II)-
(Cys)3His and Zn(II)-(Cys)2(His)2 sites were also examined with similar results and 
dissociation constants of 0.7 fM (and -20.7 kcal mol-1 contribution to protein stability) 
and 40 fM (-18.3 kcal mol-1 contribution), respectively. The observation that the Cys 
thiolate is better ligand for Zn(II) than His is again consistent with literature 
precedent.204–207 However, it should be noted that at physiological pH (7.4) the 
contributions from each of the differing coordination motifs are equal, due to proton 
competition with the thiolate ligands (Kd = 0.5 pM) and there is a -16.8 kcal mol-1 
energetic contribution to the protein-folding driving force. In natural proteins, which can 
have weaker binding affinities for the same coordination motifs, the difference is due to 
the loss of Zn(II)-binding energy to the protein folding process. 
The work described in this section, although focused on structural zinc sites, is 
important in the context of my dissertation because it highlights several aspects of metal 
binding and protein folding that must be considered when designing zinc 
metalloenzymes. The energetic cost of protein folding should be both minimized in the 
apo form and in the metal-bound form to minimize the reorganization requirements upon 
metal binding. Next, the binding of metal should be optimized towards the folded state 
rather than the unfolded state while keeping the structure flexible enough to allow for 
metal binding. Although very high binding affinities may be achieved for unfolded 
structures such as designed peptides IGA and GGG and natural ZFs, catalytic zinc sites 
 
Figure 1-25. Molecular model of Zn(II)-GGG complex with a Cys4 site rendered 
using Biosystem Insight II. Figure reproduced from ref. 213. 
!
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will likely require further structural contributions from a larger protein matrix for the 
stabilization of unsaturated coordination spheres and substrate binding. Additionally, 
while Cys residues can clearly provide more favorable Zn(II)-ligand interactions, their 
effects on the Lewis acidity of the Zn(II) center must be considered and will be discussed 
below. Therefore, designing catalytic zinc sites will require striking a balance between 
strong enough Zn(II) binding to promote catalysis (the affinities achieved using IGA and 
GGG variants are certainly higher than those observed for effective native Zn(II) 
enzymes) and formation of well-folded protein structures. 
 
Metal-mediated stabilization towards the preparation of designed multimeric structures 
Another approach to the design of structural metal sites (and, in some cases, 
catalytic sites) in proteins that is gaining ground in recent years is to use the binding 
energy provided by metals to direct the folding and assembly of multiple protein subunits 
and even extended nanostructures. Although metalloprotein design is typically associated 
with incorporating stable metal sites into protein cores, metal-protein surface interactions 
are at least equally significant and metal sites are often located at the interfaces of 
multimeric protein complexes. Additionally, the formation of metal sites at protein 
interfaces has been proposed as a possible evolutionary route towards efficient 
metalloenzymes. Therefore, gaining a full understanding of how this might occur through 
a design approach should prove very important. This topic has been reviewed36,37,218, but 
the strategy has since expanded to include the generation of periodic protein arrays38 and, 
as will be mentioned below and discussed in Chapter 2, in the design of a hydrolytic zinc 
metalloenzyme18,39. Briefly, the Tezcan group has focused on using metal-coordinating 
motifs on the surface of a monomeric protein, cytochrome cb562, to engineer novel 
protein-protein interaction interfaces in order to control the assembly of proteins. The 
initial model system, MBPC-1 (metal-binding protein complex), has two bis-His motifs 
on its surface which, upon addition of equimolar amounts of divalent metals (Zn(II), 
Cu(II), Ni(II)), forms discrete multimeric structures according to the stereochemical 
preferences of the metal ions.36,219,220 Subsequent computational redesign using 
RosettaDesign221 optimized the hydrophobic packing between interfaces and included 
some additional hydrogen-bonding and salt bridge interactions to convert the Zn(II)-
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mediated tetramer into a structure that could self-assemble even in the absence of 
metals.222 Tezcan also successfully incorporated non-natural chelates onto the surfaces to 
generate not only coordinatively unsaturated metal sites, but also a site that enforces a 
non-preferred geometry on a metal due to the steric bulk of the chelates and lattice 
packing arrangements that hold the metal centers in close proximity (Figure 1-26).223 
This is of particular importance to the design community since an efficient 
metalloenzyme often requires coordinatively unsaturated metal sites with strained metal 
geometries. Achieving this requires a structure that strikes the delicate balance between 
thermodynamic stability at the metal site and over the whole protein structure. 
 
Reengineering pre-existing metal sites for hydrolytic activity 
Beyond the introduction of Zn(II)-binding sites into both de novo and existing 
protein scaffolds through the variety of approaches discussed above, existing Zn(II)-
binding sites can be redesigned to introduce new functions or alter existing functions. The 
 
 
Figure 1-26. a) Crystal structure of the Zn:MBPPhen2 dimer (3MNK).223 b) 
Superposition of Ni:MBPPhen2 (yellow) and Zn:MBPPhen2 (magenta) metal 
centers. c) Close-up view showing the proximity between the coordinatively 
unsaturated metal centers in the asymmetric unit of the Zn:MBPPhen22 
structure. 2Fo-Fc electronic density map is contoured at 1.2 σ. The dimer is 
formed both in solution and the solid-state. Reproduced from ref. 37. 
!
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approaches have ranged from single ligand substitutions (converting ZF structural sites to 
hydrolytic sites224,225) to more extensive redesign approaches (for example, converting 
glyoxalase II to a β-lactamase33). Additionally (although I will not go into extensive 
detail here), there are several examples of using Zn(II)-binding sites to control or alter 
different protein functions. These studies range from the design of Zn(II)-binding sites 
for inhibition226,227 or control of specificity of protease activity in trypsin228–230 to Zn(II)-
induced conformational changes for sensing231–233 and control of various protein 
functions234,235. 
While there are many examples of redesigned ZF peptides, here I will focus on 
those in which the goal is to prepare a hydrolytic site.224,225 One route to the design of 
catalytic Zn(II) sites is to take an existing structural site and remove a ligand to create an 
open coordination sphere for binding and activation of external ligands. This was first 
attempted by Merkle and coworkers, who reported a truncated Zn finger peptide, CP1-C4 
(CP1: PYKCPECGKSFSQKSDLVKHQNTHTG) in which the last four residues 
(including a His) were removed, to create a peptide which binds Co(II) tetrahedrally.236 
While evidence of an open coordination site was obtained by examining the spectra of 
Co(II)-peptide complexes with external ligands, neither Zn(II) or Co(II) complexes 
displayed any hydrolytic activity, a result proposed to be due to the high pKa expected for 
a thiolate-rich site with no secondary interactions. Later, Nomura et al. reported the first 




Figure 1-27. ZF peptides. a) Amino acid sequence of ZF parent peptide. 
Reproduced from ref. 224. b) Natural ZF fold (αββ structure), and c) ZF 
αββ fold modified as a metallo-hydrolase. Both b) and c) reproduced from ref. 
250. 
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RPFMCTWSYCGKRFTRSDELQRHKRTHTGE, zf(CCHH)) into a hydrolytic Zn(II) 
site by preparing a series of ZF mutants in which one of the coordinating residues was 
substituted with a non-coordinating residue (Ala or Gly) (Figure 1-27a).224,237,238 For 
those mutants retaining at least one Cys in the coordination sphere, Co(II)-substitution 
indicated four- or five-coordinate geometries. The highest activity (pNPA hydrolysis) 
was observed for zf(CCHA), which has a sequence similar to the truncated ZF CP1-C4 
and four-coordinate geometry (with an open site) and a second order rate constant of 
0.568 ± 0.0228 M-1 s-1. The Zn(II) center is located in a more hydrophobic environment 
in zf(CCHA) than in CP1-C4236 due to the presence of the C-terminal residues, which can 
affect both substrate binding and also the acidity of the Zn(II)-bound water molecule.239 
All of the other mutants with at least one Cys in the coordination sphere were five-
coordinate, including two vacant sites. Generally, ZFs of the CHH-type displayed higher 
activities than those of the CCH type, probably because the Cys residue can decrease the 
Lewis acidity of the Zn(II) center via its electron-donating ability and, consequently, 
reduce the activity (Table 1-5). To this end, the authors prepared several HHH-type ZFs, 
which should bind as neutral ligands (as in CA) and help maximize the Lewis acidity. As 
expected, increased activity was observed relative to the Cys-containing ZFs (up to 0.966 
± 0.0492 M-1 s-1 for zf(HHHH)). While only rarely seen in nature (for example, a 
structural site in the HAP1 transcriptional factor240), a ZnHis4 site has also been observed 
in a related redesigned ZF protein241 and in the MBPC-2 system reported by Salgado et 
al.242, but no activity was reported for either. Co(II)-substitution of all of these, however, 
indicated six-coordinate geometries, with at least two vacant sites, although, given the 
preference of Co(II) for octahedral geometries, lower coordination numbers for Zn(II) 
cannot be ruled out. The hydrolysis of pNPA as performed by these ZF mutant peptides is 
pH-dependent with pKa values ranging from 6.3 to 7.6 that increase as expected based on 
the Lewis acidity of the Zn(II) center. The activity of the His4 site falls within the range 
of those reported for synthetic small molecule model complexes in mostly aqueous 
conditions243–247, yet remains almost 3000-fold slower than CAII.171,248 zf(HHHH) also 
displayed nuclease activity towards substrates bis(p-nitrophenyl) phosphate and 
supercoiled plasmid DNA (pUC19GC).249 Overall, this work demonstrates the 
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importance of having primarily neutral ligands in the coordination spheres of Zn(II) 
centers in hydrolytic enzymes. 
In another study, a ZF protein (αββ fold) is targeted for computational redesign as 
a hydrolyase (Figure 1-27c).250 In this design method, CYANA and then IDeAS were 
used to design a linker between D-amino acid-nucleated secondary structures (α-helix and 
two β-hairpins) and to optimize the sequence, respectively. The resulting small 21-mer 
sequence with αββ structure bound Zn(II) with Kd ~800 µM and ΔGo of ~ -17.2 kJ mol-1. 
Therefore, Zn(II) binding to this His3 site is weaker than for any of the other designs 
discussed above (Table 1-4). Hydrolysis of pNPA was observed with an initial rate of 
103.45 (±0.25) x 10-9 M s-1, a 45-fold enhancement over the background at pH 7.0 and 25 
°C. However, enzyme-like hydrolysis with substrate binding was not observed, possibly 
because the short sequence and small size of the fold do not provide enough protein 
structure to support substrate binding. 
Although there are many examples of zinc metalloenzymes which have been 
studied through alteration of their zinc coordination spheres, none have been more 
extensively reengineered than CA. Because this enzyme has been systematically studied 
and represents a desirable goal for achieving efficient hydrolytic designed zinc 
metalloproteins (and is the model system for the designs I will discuss in Chapters 2-5), I 
Table 1-5. Coordination environments and pNPA hydrolysis rate 
constants of zinc finger mutant peptides.a 
ZF variant Coordination #  (# vacant sites)b 
pNPA hydrolysis rate 
constant (M-1 s-1) 
Zn(II)-zf(CCHH) 4 (0) 0 
Zn(II)-zf(CCGH) 5 (2) 0.218 ± 0.0085 
Zn(II)-zf(CCAH) 5 (2) 0.232 ± 0.0051 
Zn(II)-zf(CCHG) 5 (2) 0.351 ± 0.0182 
Zn(II)-zf(CCHA) 4 (1) 0.568 ± 0.0228 
Zn(II)-zf(GCHH) 5 (2) 0.399 ± 0.0014 
Zn(II)-zf(CGHH) 5 (2) 0.458 ± 0.0021 
Zn(II)-zf(AHHH) 6 (3) 0.478 ± 0.0057 
Zn(II)-zf(HAHH) 6 (3) 0.497 ± 0.00058 
Zn(II)-zf(HHAH) 6 (3) 0.370 ± 0.0289 
Zn(II)-zf(HHHA) 6 (3) 0.443 ± 0.0147 
Zn(II)-zf(HHHH) 6 (2) 0.966 ± 0.0492 
a. Taken from ref. 224. In 20 mM HEPES buffer (pH 7.5), 0.1 M NaCl, 
3.5% acetonitrile, 25 °C. 
b. Based on Co(II)-substituted UV-Vis absorption studies. 
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will summarize selected reengineering studies for CA (Figure 1-28). The direct metal-
binding residues around the Zn(II) site (His94, His96, and His119) have been replaced by 
a variety of amino acids (Asp, Glu, Asn, Gln, Cys, Ala) in order to study the effects on 
the first coordination sphere.189,251 Early work involved the preparation of the mutant 
His94Asp, which resulted in a tetrahedral His2Asp coordination environment with a 
solvent molecule.252 A loss in metal-binding affinity of ~104-fold was observed (Kd = 15 
nM, Table 1-6), probably in part due to movement of the Zn(II) ion ~1 Å towards the Asp 
residue, resulting in interruption of the evolved His3 ligand arrangement. Changes in the 
electrostatics of the site (neutral to anionic substitution) also lead to an increase in the pKa 
from 6.8 to > 9.6. A larger loss in Zn(II)-binding affinity is observed when His94 is 
replaced by Ala (Kd = 270 nM).251 Substitution of the same His residue with a Cys also 
results in a loss of Zn(II)-binding affinity of ~104-fold (Zn(II) movement is essentially 
the same as for H94D) and an increase of the pKa to > 9.5.251,253 Overall, changes to the 
charge of the Zn(II) site by addition of charged residues results in severe losses to 
 
 
Figure 1-28. Structure of the active site of carbonic anhydrase II. a) The extended 
active site of CAII showing the ordered water network (pdb 3KS3).269 Zn(II) is 
represented by a gray sphere, and the oxygen atoms of water molecules are 
shown as smaller red spheres. The dotted lines represent presumed hydrogen 
bonds. Selected amino acids of the active site are shown as stick figures with both 
the inward and outward orientations of His64 (proton shuttle) shown. This figure 
was created with PyMOL.264 b) ChemDraw scheme of the CAII primary and 
secondary Zn(II)-binding site. 
!
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catalytic activity (altered Lewis acidity of Zn(II)). However, when alternate neutral 
residues (Asn, Gln) are introduced, reasonable catalytic activity is retained, although 
losses in binding affinity of ~104-105-fold are still observed.166 Altering the other His 
positions in similar ways gives similar results.251,254 Interestingly, a route towards 
improving the affinity of Zn(II) for CA has also been taken by substituting a nearby 
residue (Thr199, which forms a stabilizing hydrogen bond with Zn(II)-bound solvent) 
with Cys, Asp, Glu, or His. Substitution with Cys results in an improvement of the Kd (to 
1.1 pM from 4 pM) and some loss in activity (~103-fold) due to an alternate conformer 
with a Zn(II)-hydroxide species.196,255 In the case of T199E, the affinity is greatly 
improved (Kd = 20 fM) and the activity is abolished due to displacement of Zn(II)-bound 
hydroxide.256 For T199H, the affinity actually decreases 20-fold as the fourth His does 
not bind to Zn(II).256 Another example which alters the secondary coordination sphere is 
mutating T199 to Ala (abolishing the hydrogen bond), which retains the His3 
coordination environment, but results in a 100-fold loss in activity and increase in the pKa 
of ~1.5 units. There are also hydrogen-bonding interactions with the unbound nitrogen of 
each of the His residues in the primary coordination sphere (His94 to Gln92, His119 to 
Glu117, and His96 to backbone of Asn244). The effects of mutating Gln92 and Glu117 
on the pKa are within ±1 unit with only subtle effects on the Kd, and usually losses in 
activity of about 10-fold or less. This is likely because the direct metal ligands will often 
replace the lost hydrogen-bonding partners with other protein sites or even solvent.257–259 
One case in which drastic effects were observed is for the E117Q mutant, in which a 
55000-fold loss in activity, increase in the pKa to > 9, and 1100-fold weaker Zn(II)-
binding affinity was reported.260 These results have been proposed to arise from reversal 
of the hydrogen bond between residue 117 and His119, stabilizing H119 as a histidinate 
anion. These studies on the primary and secondary coordination sphere of CA clearly 
demonstrate many of the characteristics of successful Zn(II) sites that should be taken 
into account in the protein design approach. Mutagenesis studies demonstrate that neutral 
His ligands in the primary coordination sphere are essential for enhancing the net positive 
charge at the Zn(II) site and secondary hydrogen-bonding interactions fine-tune Zn(II)-
binding affinities and Zn(II)-OH2 pKa’s. 
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There are also several reports on the redesign of CA for improved activity 
towards alternate ester substrates, in which controlling the steric interactions within the 
hydrophobic pocket can lead to altered substrate specificities and esterase 
activities.172,261–263 Therefore, protein design efforts should consider how size and charge 
interactions of the desired substrates could affect activity and control selectivity. 
An example of more extensive reengineering of a zinc metalloenzyme is the 
computational redesign of the dizinc-containing glyoxalase II enzyme (which hydrolyzes 
thioester bonds) into a β-lactamase through extensive modifications made through 
insertion, deletion, and substitution of several active site loops and subsequent point 
mutations.33 This redesign altered the metal-binding geometry as well as the substrate-
Table 1-6. Active site properties for carbonic anhydrase II and selected mutants. 









type His3O 0.8 ± 0.1
(a) 6.8 ± 0.1(b) 110 ± 10(c) 2600 ± 50
(c) 
Primary coordination sphere mutants 
H94Dd,e His2Asp 15000 ± 5000 ≥ 9.6 0.11 ± 0.01 365 ± 70 
H94Ae His2 270000 ± 50000  0.012 ± 0.0002 18 
H94Ce,f His2Cys 33000 ± 7000 ≥ 9.5 0.11 ± 0.01 117 ± 20 
Secondary coordination sphere mutants 
T199Cg,h His3Cys 1.1 ± 0.2  0.11 ± 0.02  
T199Di His3Asp 4 ± 0.02  0.04 ± 0.005  
T199Ei His3Glu 0.02 ± 0.01  0.04 ± 0.005  
T199Hi His3O 77 ± 13 ≥ 9.0 0.024 ± 0.002  
T199A His3O 60 ± 10(j) 8.3 ± 0.1(c) 1.1 ± 0.05(c) 
44 ± 2(c) or 
15(k) 
E117Ql His3O 4400 ± 400 ≥ 9.0 0.002 3 
a. Taken from reference 270. 
b. Taken from reference 271. 
c. Taken from reference 272. 
d. Taken from reference 252. 
e. Taken from reference 251. 
f. Taken from reference 253. 
g. Taken from reference 255. 
h. Taken from reference 196. 
i. Taken from reference 256. 
j. Taken from reference 258. 
k. Taken from reference 273. 
l. Taken from reference 260. 
!
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binding pocket, yet both glyoxalase II and metallo β-lactamase enzymes contain 
binuclear metal ions essential to the hydrolysis reaction. While a designed dinuclear zinc 
site is present in the de novo designed due ferri (DF) family of proteins (Section 3a)15, no 
activity has been reported for any dinuclear zinc site introduced into any de novo or 
preexisting metal scaffold that did not already contain a Zn2 site. 
 
c) From zinc-binding proteins to hydrolytic metalloenzymes 
 
Until recently, designed zinc metalloproteins have often shown very little, if any, 
catalytic activity relative to their natural counterparts and few have been structurally 
characterized. As discussed above, there are examples where preexisting Zn(II) sites have 
been redesigned for different functions, such as converting gloyoxalase II to a metallo-β-
lactamase33 and converting ZF peptides (closed coordination spheres) to catalytic sites by 
opening up the first coordination sphere,236 but generating hydrolytic activity from a 
“new” zinc site either in a de novo or pre-existing protein scaffold had not yet been 
achieved. In early 2012, I reported the first example of a hydrolytically active de novo 
designed zinc site (Chapter 2).70 Soon after, Khare et al. reported the de novo 
computational redesign and subsequent directed evolution of a Zn(II)-containing mouse 
adenosine deaminase for efficiently catalyzing the hydrolysis of a model 
organophosphate substrate.19 Not long after that, Der et al. reported the de novo design of 
a ZnHis3 site at the computationally-designed interface between two copies of the Rab4-
binding domain of Rabenosyn which effectively catalyzes the hydrolysis of both pNPA 
and p-nitrophenyl phosphate (pNPP).18,39 In the following chapters, I will present my 
work on the design of a dual-site combined structural and functional metalloprotein for 
Zn(II)-dependent hydrolysis. 
In the second chapter of my thesis, I have described the preparation and 
characterization of a de novo designed protein (a homomeric parallel 3SCC and 
derivative of the TRI peptide sequence), which can bind two different metals in spatially 
separated sites, with different functions. The sequence used, TRIL9CL23H, contains a 
Cys substitution in the 9th position and His in the 23rd position. The Cys3 site exploits the 
Hg(II)-binding studies described in Section 2b in order to function as a structurally 
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stabilizing  metal site. The His3 site binds transition metals such as Zn(II) and represents 
a catalytic metal site. The minimal ZnN3O site achieved in this α-helical coiled coil 
peptide allows me to address the question of whether a minimal structural unit in a de 
novo protein can achieve significant enzyme-like hydrolytic activity. Further, the 
inclusion of a structurally stabilizing site sets the stage for comparison to an analogous 
complex lacking the site and allows for determination of its effects on the activity of the 
ZnN3O site. This is particularly important for developing multi-metal site proteins where 
one may want to incorporate multiple metal sites for a variety of functions. 
In the third chapter of my thesis, I address the effects of varying the position of 
the ZnN3O site along the sequence of the TRI peptide and its insertion into the analogous 
Grand peptide. As discussed in Section 4b, the location of a ZnHis2Cys2 site in Trx can 
significantly affect Zn(II)-binding affinities and be correlated with the stability of the 
complex.212 One example in which the effects of site location on catalysis was examined 
also involved the redesign of Trx (in order to incorporate a mononuclear non-heme iron 
site for superoxide dismutase function), and significant functional differences were 
observed.30 By testing two additional site locations along the TRI sequence 
(TRIL9HL23C and TRIL9CL19H) and its insertion into Grand  (GRL2WL16CL30H), 
I address whether location of a minimal active site may affect catalytic rate, binding 
affinity, substrate, solvent, and inhibitor access, Zn(II)-OH2 pKa, and catalytic efficiency. 
Understanding whether these properties may be controlled is important to the design of 
secondary interactions, including hydrogen-bonding networks. 
In the fourth chapter of my thesis, I describe the preparation of additional 
designed peptides towards the development of hydrogen-bonding networks. I have 
inserted polar residues (Thr, Asp) into TRI and Grand sequences around the ZnN3O site 
and establish first: whether the peptide can accommodate the substitution and remain 
folded; second: the binding strength of Zn(II) to each site and how it compares to original 
sites; and third: the effects these substitutions have on catalytic activity. Then, in order to 
establish a method for readily interpreting these results in solution, I describe the binding 
of Cd(II) and Co(II) to TRIL2WL23H and Co(II) to those sequences containing polar 
residues. These metals are commonly used as spectroscopic probes for the Zn(II) site in 
many native metalloenzymes, including CA. 
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In the fifth chapter of my thesis, I describe the hydrolytic activity of the designed 
ZnN3O site in several of these peptides towards the physiological substrate of CA, CO2. 
Although pNPA represents an excellent model substrate for measuring the activity of 
many model complexes, designed proteins, and even native enzymes, it does not 
represent the evolved activity of the target enzyme, CA. Here, I describe this activity and 
present comparisons between active sites at different peptide locations and then address 
how these results may compare to those obtained for pNPA hydrolysis. 
Finally, in the sixth chapter of my thesis, I conclude with the key achievements 
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